2,7-Substituted Pyrrolo[2,1-f][1,2,4]triazine Compounds with Inhibitory Activity against Protein Kinases
Patent Information
- Application Number
- JP2024532728
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-29
- Filing Date
- 2022-11-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
【0040】 本発明が特徴とする前記化学式1で表される2,7-置換されたピロロ[2,1-f][1,2,4]トリアジン分解剤化合物、その薬学的に許容される塩、その水化物またはその溶媒化物は、ABL1、ABL2、ALK、ARK5、Aurora A、Aurora B、Aurora C、AXL、BLK、BMX、BRK、c-Kit、c-MER、c-Src、CAMK2a、CAMK2d、CDK16、CDK17、CDK18、CDK2/cyclin A、CDK2/cyclin O、CDK4/cyclin D1、CDK4/cyclin D2、CDK4/cyclin D3、CDK6/cyclin D1、CDK6/cyclin D3、CDK7/cyclin H、CDK9/cyclin K、CDK9/cyclin T1、CDK9/cyclin T2、CK2a、CK2a2、CLK1、CLK2、CLK4、DAPK1、DAPK2、DDR1、DDR2、DRAK1、DYRK1/DYRK1A、DYRK1B、DYRK3、EPHA1、EPHA2、EPHA4、EPHA5、EPHA6、EPHA7、EPHB1、EPHB2、ERBB4/HER4、ERK7/MAPK15、ERN2/IRE2、FAK/PTK2、FER、FES/FPS、FGFR1、FGFR2、FGFR3、FGR、FLT1/VEGFR1、FLT3、FLT4/VEGFR3、FMS、FRK/PTK5、FYN、GLK/MAP4K3、GSK3a、HIPK2、HIPK3、HIPK4、HPK1/MAP4K1、IGF1R、IKKe/IKBKE、IR、IRAK1、IRR/INSRR、JAK1、JAK2、JAK3、JNK1、JNK2、JNK3、KDR/VEGFR2、KHS/MAP4K5、LCK、LIMK1、LIMK2、LRRK2、LYN、LYN B、MAK、MARK1、MARK2/PAR-1Ba、MARK3、MARK4、MAST3、MEKK2、MELK、MLCK2/MYLK2、MLK1/MAP3K9、MLK2/MAP3K10、MLK3/MAP3K11、MUSK、MYLK4、NEK1、NEK2、NEK5、NEK9、p70S6K/RPS6KB1、PAK4、PAK5、PAK6、PDGFRa、PDGFRb、PHKg1、PHKg2、PKAcb、PKCa、PKCb2、PKCg、PKCmu/PRKD1、PKCnu/PRKD3、PKD2/PRKD2、PKN1/PRK1、PLK4/SAK、PRKX、PYK2、RET、ROS/ROS1、RSK2、RSK3、RSK4、SIK1、SIK2、SLK/STK2、SNARK/NUAK2、STK16、STK22D/TSSK1、STK33、STK38/NDR1、STK38L/NDR2、STK39/STLK3、SYK、TBK1、TEC、TIE2/TEK、TLK2、TNK1、TRKA、TRKB、TRKC、TYK2、TYRO3/SKY、ULK1、ULK2、ULK3、WEE1、YES/YES1、YSK4/MAP3K19及びZIPK/DAPK3のうち何れか1つ以上であるキナーゼの活性を分解及び阻害する能力に優れているので、非正常な細胞成長によって誘発される疾患の予防、軽減または治療剤として有用である。
Smart Images

Figure 2024542735000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound having inhibitory activity against protein kinases, a pharma- ceutical composition containing the compound as an active ingredient for preventing, alleviating or treating a disease induced by abnormal cell growth. [Background technology]
[0002] Protein kinases in normal cells are in balance between active and inactive states and are involved in cellular phenomena (signal transmission, transport, secretion, growth, division, cycle, etc.). When protein kinases are overactivated due to gene mutation, amplification, overexpression, etc., the cell signaling system is overactivated, inducing the development / growth / metastasis of cancer cells. Representative kinases that induce the development or growth of cancer cells when abnormally regulated include EGFR, ALK, DDR, BRAF, FGFR, VEGFR, BTK, MET, AKT, HER2, RET, NTRK, mTOR, MEK, ROS1, FLT3, c-kit, ABL1, PDGFR, etc.
[0003] Acute myeloid leukemia (AML) is the most common form of leukemia. It is a disease in which osteoblasts abnormally proliferate in bone marrow or peripheral blood (accounting for more than 20%) and normal hematopoietic cells decrease in proportion, suppressing hematopoietic function. It is known that 25-30% of AML patients have FLT3 gene mutated to internal tandem duplication (FLT3-ITD). In addition, point mutations (F691L, D835Y, etc.) occurring within the kinase domain of FLT3 have been reported continuously. It is widely known that these induce continuous autophosphorylation of FLT3, overactivating signals related to the proliferation and division of cancer cells, thereby inducing AML.
[0004] Lung cancer is a malignant tumor that occurs in the lungs and is known to be the leading cause of cancer-related deaths worldwide. It can be divided into small cell lung cancer and non-small cell lung cancer depending on the histological type, and approximately 85% of all lung cancer patients are non-small cell lung cancer patients. Non-small cell lung cancer can be cured completely through surgery in the early stages, but symptoms do not appear in the early stages of lung cancer, making early diagnosis difficult, and the percentage of patients who can undergo surgery is low. Even if the initial surgery is successful, the recurrence rate is high and metastasis to other organs such as the brain, bones, liver, and lymph nodes occurs more frequently than other cancers. Even with concurrent chemotherapy and radiation therapy, the prognosis is poorer than other cancers. The 5-year survival rate is also very low at less than 10%.
[0005] EGFR (Epidermal growth factor receptor) is a tyrosine kinase receptor known to be the most important cause of non-small cell lung cancer. Among non-small cell lung cancer patients, 30-40% in Asia and 10-15% in the United States and Europe have EGFR mutations. Approximately 95% of EGFR mutations activate EGFR regardless of the presence or absence of ligand binding, with EGFR exon 19 mutations being the most frequent at 45%, and point mutations in exon 21 (L858R) accounting for 40%.
[0006] Breast cancer refers to a malignant tumor that occurs in the breast. Breast cancer is the most common female cancer in the world, accounting for 24.2% of all female cancers and has the highest mortality rate at about 15%. The number of breast cancer patients in Korea and worldwide has been steadily increasing. The number of breast cancer patients increased by about 41% from 2015 (156,533) to 2019 (222,014). In particular, triple-negative breast cancer (TNBC), an aggressive form of breast cancer, accounts for 10-20% of all breast cancers, and the mortality rate of triple-negative breast cancer in the United States is about 50%.
[0007] Colorectal cancer ranks third among all cancers in terms of awareness (6.1%) and second in terms of mortality (9.25). Total deaths from rectal and colon cancer are projected to increase by 60% and 71.5%, respectively, through 2035. More than 1.9 million new cases of colorectal cancer occurred in 2020.
[0008] Approximately 1.3 million new cases of prostate cancer are diagnosed annually worldwide. Currently, over 10 million men are diagnosed with prostate cancer, of which approximately 700,000 are metastatic prostate cancer patients. Metastatic prostate cancer causes over 400,000 deaths annually, and the mortality rate from metastatic prostate cancer is predicted to more than double by 2040.
[0009] Gastric cancer is the fourth leading cause of cancer deaths worldwide, with a median survival rate of less than 12 months at advanced stages. The average age at diagnosis of gastric cancer is 70 years, although approximately 10% of cases are found at age 45 or younger.
[0010] The global prevalence of liver cancer is predicted to exceed one million cases by 2025. Hepatocellular carcinoma (HCC), the most common form of liver cancer, accounts for approximately 90% of all liver cancer cases. The main causes of HCC are infection with hepatitis B and C viruses, but diabetes-related nonalcoholic steatohepatitis and metabolic syndrome are also risk factors for liver cancer.
[0011] Therefore, the present inventors have conducted research to develop novel substances capable of overcoming the above-mentioned diseases, and have completed the present invention. [Prior art documents] [Patent documents]
[0012] [Patent Document 1] WO 2010-071885 [Patent Document 2] WO 2014-193932 [Non-patent literature]
[0013] [Non-Patent Document 1] Org.Lett.2011,13,4204-4207 [Non-Patent Document 2] J. Med. Chem. 2011, 54, 6328-6341 [Non-Patent Document 3] J. Med. Chem. 2012, 55, 115-125 Summary of the Invention [Problem to be solved by the invention]
[0014] It is an object of the present invention to provide novel 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds having inhibitory activity against protein kinases.
[0015] Another object of the present invention is to provide a pharmaceutical composition useful for treating, preventing and alleviating cancer diseases, which contains a novel 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound, a pharma- ceutically acceptable salt thereof, a hydrate thereof, a solvate thereof or a stereoisomer thereof as an active ingredient.
[0016] Another object of the present invention is to provide a therapeutic agent for cancer disease, which comprises, as an active ingredient, a novel 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound, a pharma- ceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, or an isomer thereof.
[0017] Another aspect of the present invention is to provide a method for producing the novel compound.
[0018] Another aspect of the present invention is to provide a novel intermediate compound synthesized during the above-mentioned production method. [Means for solving the problem]
[0019] One aspect of the present invention provides a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by the following chemical formula 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof:
[0020] [ka]
[0021] In the above Chemical Formula 1,
[0022] R1, R2 and R3 are each independently hydrogen; a hydroxyl group; a halogen group; 13 Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); ester group (-C(O)OR8); carboxylic acid group (-C(O)OH); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0023] A and B are each independently C6-C 10 Aryl group; C3-C 10 Cyclyl group; C3-C 10 Heteroaryl groups; or C3-C 10 a heterocyclyl group;
[0024] R4, R5, R6 and R7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 13 Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0025] L a is hydrogen; hydroxyl group; halogen group; C1-C 13Alkyl group; -Z a -Q3-E; or -Z a -Q1-M; a -Q1-M, where M is L b Ga-Z b -Q2, which is linked to Q2 to form a ring;
[0026] L b is hydrogen; hydroxyl group; halogen group; C1-C 13 Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl; amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or -Z b -Q2; and -Z b -Q2, where Q2 is L a Ga-Z a -Q1-M is linked to M to form a ring;
[0027] Said Z a or Z b may or may not exist independently, Z a or Z b If there is Z a or Z b are each independently -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2 )-, -C3-C 10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0028] Q1, Q2 and Q3 each independently represent -C n H n+2 -, -O(C n H n+2 )-, -(OC2H4) n -, -(C2H4O) n -, -(C n H n+2 )O-, -(C n H n+2 )CO-, -NR8(C n H n+2 )-, -(NR8C2H4) n -, -(C2H4NR8) n -, -(C n H n+2 )NR8-, -(C n H n+2 )O(C m H m+2 )-, -(C n H n+2 )O(C m H m+2 )CO-, -C3-C 10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0029] The Q4 may be present or absent, and when present, -C n H n+2 -, -C n H n - or -C n H n-2 - and
[0030] The M is -O-, -CO-, -COO-, -C2H2-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2)-, -NR8-; -NR8CH2-; -NHR8-; -NR8C(O)-; -NR8C(O)O-; -C(O)NR8-; -NR8C(O)NR8-; -NC(O)R8-; -NS(O)2R8-; -S(O)2-; -NR8S(O)2-; and -S(O)2NR8-;
[0031] The n and m each independently represent an integer of 0 to 15,
[0032] The E is [ka] or [ka] and
[0033] X2, X3 and X4 each independently represent a hydrogen atom; a halogen group; 13 Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0034] the X1 is present or absent, and if present, X1 is -CR8R9-, -O- or -NR8-;
[0035] The Y1, Y2, Y3 and Y4 each independently represent a C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; C3-C 10 Cyclyl group; or C3-C 10 a heterocyclyl group;
[0036] R8 and R9 are each independently hydrogen; a C1-C6 alkyl group; a C1-C6 alkenyl group; a C1-C6 alkynyl group; a C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; C3-C 10 Cyclyl group; C3-C 10 or R8, together with the nitrogen or carbon atom connected to R9, can optionally contain at least one of N, O, S, NH, C=N, C=O, -NHC(O)-, -NHC(O)NH-, -NHS(O)2-, or SO2, and can be selected from hydrogen, C1-C 13 Alkyl groups, C6-C 10 Aryl groups, C3-C 10 forming a 3- to 7-membered saturated ring optionally substituted with at least one of a heteroaryl group, a hydroxyl group, a halide group, and a cyano group;
[0037] The C1-C6 alkoxy group, C1-C 13 Alkyl group or C3-C 10 Cyclyl groups are hydrogen; hydroxyl; halogen; C1-C 13 Alkyl group; C1-C6 alkoxy group; Amino group (-NR8R9); Nitro group (-N(O)2); Amide group (-(C=O)NR8R9); Carboxylic acid group (-C(O)OH); -Ester group (-C(O)OR8); Nitrile group (-CN); Urea group (-NR8(C=O)NR9-); Sulfonamide group (-NHS(O)2-); Sulfide group (-S-); Sulfone group (-S(O)2-); Phosphoryl group (-P(O)R8R9); C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0038] Said C6-C 10 Aryl groups, C3-C 10 Heteroaryl group or C3-C 10A heterocyclyl group is a group selected from the group consisting of hydrogen, hydroxyl, halogen, carbonyl (-(C=O)R8R9), halogen or C3-C 10 C1-C3 alkyl groups substituted or unsubstituted with heterocyclyl groups; halogen or C3-C 10 C1-C3 alkoxy groups, substituted or unsubstituted with heterocyclyl groups; C6-C 10 Phenoxy; Amino group (-NR8R9); Amide group (-(C=O)NR8R9); C6-C 10 Aryl group; C3-C 10 Heteroaryl groups and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0039] Said C3-C 10 Heteroaryl groups and C3-C 10 The heterocyclyl group contains one or more heteroatoms selected from the group consisting of N, O, and S. Effect of the Invention
[0040] The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine decomposer compound represented by the above-mentioned chemical formula 1, its pharma- ceutically acceptable salt, its hydrate or its solvate, which are characteristic of the present invention, are ABL1, ABL2, ALK, ARK5, Aurora A, Aurora B, Aurora C, AXL, BLK, BMX, BRK, c-Kit, c-MER, c-Src, CAMK2a, CAMK2d, CDK16, CDK17, CDK18, CDK2 / cyclin A, CDK2 / cyclin O, CDK4 / cyclin D1, CDK4 / cyclin D2, CDK4 / cyclin D3, CDK6 / cyclin D1, CDK6 / cyclin D3, CDK7 / cyclin H, CDK9 / cyclin K, CDK9 / cyclin T1, CDK9 / cyclin D2, CDK7 / cyclin H, CDK9 / cyclin K, CDK9 / cyclin T2, CDK7 / cyclin H, CDK9 / cyclin K, CDK9 / cyclin T3, CDK7 / cyclin H, CDK9 / cyclin K, CDK9 / cyclin T4, CDK9 / cyclin T5, CDK9 / cyclin T6, CDK9 / cyclin T7, CDK9 / cyclin T8, CDK9 / cyclin T9, CDK9 / cyclin T10, CDK9 / cyclin T11, CDK9 / cyclin T12, CDK9 / cyclin T13, CDK9 / cyclin T14, CDK9 / cyclin T15, CDK9 / cyclin T16, CDK9 / cyclin T17, CDK9 / cyclin T18, CDK9 / cyclin T19, CDK9 / cyclin T19, CDK9 / cyclin T19, CDK9 / cyclin T19, CDK9 / cyclin T21, CDK T2, CK2a, CK2a2, CLK1, CLK2, CLK4, DAPK1, DAPK2, DDR1, DDR2, DRAK1, DYRK1 / DYRK1A, DYRK1B, DYRK3, EPHA1, EPHA2, EPHA4, EPH A5, EPHA6, EPHA7, EPHB1, EPHB2, ERBB4 / HER4, ERK7 / MAPK15, ERN2 / IRE2, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGR, F LT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GLK / MAP4K3, GSK3a, HIPK2, HIPK3, HIPK4, HPK1 / MAP4K1, IGF1R, IKKe / I KBKE, IR, IRAK1, IRR / INSRR, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LCK, LIMK1, LIMK2, LRRK2, LYN, LYNB, MAK, MARK1, MARK2 / PAR-1Ba, MARK3, MARK4, MAST3, MEKK2, MELK, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, MYLK4, NEK1, NEK2, NEK5, NEK9, p70S6K / RPS6K B1, PAK4, PAK5, PAK6, PDGFRa, PDGFRb, PHKg1, PHKg2, PKAcb, PKCa, PKCb2, PKCg, PKCmu / PRKD1, PKCnu / PRKD3, PKD2 / PRKD2, PKN1 / PRK1, PLK4 / SAK, PRKX, PYK2, RET, ROS / ROS1, RSK2, The compound has an excellent ability to degrade and inhibit the activity of any one or more of kinases selected from the group consisting of RSK3, RSK4, SIK1, SIK2, SLK / STK2, SNARK / NUAK2, STK16, STK22D / TSSK1, STK33, STK38 / NDR1, STK38L / NDR2, STK39 / STLK3, SYK, TBK1, TEC, TIE2 / TEK, TLK2, TNK1, TRKA, TRKB, TRKC, TYK2, TYRO3 / SKY, ULK1, ULK2, ULK3, WEE1, YES / YES1, YSK4 / MAP3K19 and ZIPK / DAPK3, and is therefore useful as an agent for preventing, alleviating or treating diseases induced by abnormal cell growth.
[0041] The abnormal cell growth diseases which may be prevented and treated by the compounds according to the present invention include various tumor diseases selected from gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenoma, uterine cancer, cervical cancer, head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer such as leukemia (acute myeloid leukemia), multiple myeloma, myelodysplastic syndrome, lymphoma such as Hodgkin's disease and non-Hodgkin's lymphoma, or fibroadenoma. [Brief description of the drawings]
[0042] [Figure 1] 13 shows the results of Experimental Example 3 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0043] definition
[0044] Unless otherwise indicated, all numbers, values and / or expressions expressing ingredients, reaction conditions, and amounts of ingredients used herein should be understood to be modified in all cases by the term "about" since such numbers are inherently approximations that reflect various uncertainties of measurement that arise in obtaining such values among others. Also, when numerical ranges are disclosed in this description, such ranges are continuous and include every value from the minimum value to the maximum value, inclusive, unless otherwise indicated. Furthermore, when such ranges refer to integers, they include every integer from the minimum value to the maximum value, inclusive, unless otherwise indicated.
[0045] When a range is described herein for a variable, the variable is understood to include any value within the described range, including the described endpoints of the range. For example, the range "5-10" is understood to include not only the values 5, 6, 7, 8, 9, and 10, but also any subranges such as 6-10, 7-10, 6-9, 7-9, etc., and any value between the integers that are valid within the described range, such as 5.5, 6.5, 7.5, 5.5-8.5, and 6.5-9. Also, for example, the range "10-30%" is understood to include not only values such as 10%, 11%, 12%, 13%, and any integers up to and including 30%, but also any subranges such as 10-15%, 12-18%, 20-30%, etc., and any value between the integers that are valid within the described range, such as 10.5%, 15.5%, 25.5%.
[0046] As used herein, the terms "individual," "subject," and "patient" refer to any mammal. In some embodiments, the mammal is a human. In some embodiments, the mammal is not a human. None of the terms require or are limited to situations characterized by the supervision (e.g., full-time or intermittent) of a health care worker (e.g., a physician, registered nurse, nurse practitioner, physician assistant, choreographer, or hospice worker).
[0047] "Treatment" is an attempt made with the intention of preventing the development or alteration of a disease lesion. Thus, "treatment" refers to both therapeutic treatment and preventive dimensions. What needs to be treated includes not only conditions that already have a disease, but also conditions in which the disease must be prevented. In tumor treatment, a therapeutic agent refers to one that directly reduces the pathology of tumor cells or makes tumor cells more sensitive to treatment with other therapeutic agents, such as radiation and / or chemotherapy and / or immunotherapy. As used herein, the term "alleviation" or "treated" refers to a sign approaching a normalized value measured by a conventional statistical test. Here, an indication approaching a normalized value is, for example, a value obtained from a healthy patient or individual that is less than 50% different from the normalized value, preferably less than 25% different, more preferably less than 10% different, and even more preferably not significantly different from the normalized value.
[0048] "Treatment of cancer" means any one or more of the following effects: 1) inhibition of tumor growth, including i) slowing or ii) complete cessation of growth; 2) reduction in tumor cell count; 3) maintenance of tumor size; 4) reduction in tumor size; 5) inhibition of tumor cell invasion into peripheral organs, including i) reduction or ii) slowing or iii) complete prevention; 6) inhibition of metastasis, including i) reduction or ii) slowing or iii) complete prevention; 7) enhancement of the anti-tumor immune response, which may result in i) maintenance of tumor size or ii) reduction in tumor size or iii) slowing of tumor growth or iv) reduction, slowing or prevention of invasion.
[0049] As used herein, an "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a compound disclosed herein to alleviate to some extent the symptoms of the disease or condition being treated (e.g., cancer or inflammatory disease, periodontal disease or soft tissue mineralization). In some embodiments, the result is 1) reduction and / or alleviation of the signs, symptoms, or causes of a disease, or 2) any other desired alteration of a biological system in a clinical setting. In some embodiments, an appropriate "effective" amount in any individual case is determined using techniques such as dose escalation studies.
[0050] In some embodiments, an "effective amount" refers to an amount of a disclosed compound in monotherapy or combination therapy, i.e., an amount that, when administered in one or more doses, is effective to inhibit EGFR by about 20% (20% inhibition), at least about 30% (30% inhibition), at least about 40% (40% inhibition), at least about 50% (50% inhibition), about 60% or more (60% inhibition), about 70% or more (70% inhibition), about 80% or more (80% inhibition), or about 90% or more (90% inhibition), when compared to EGFR activity in an individual not treated with the compound or when compared to EGFR activity in an individual before or after treatment with the compound.
[0051] In some embodiments, a "therapeutically effective amount" refers to an amount of a disclosed compound, i.e., an amount administered in one or more doses, in a monotherapy or combination therapy, that is effective to reduce the tumor burden in a subject by about 20%, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, or about 90% or more, when compared to the tumor burden in a subject not treated with the compound, or when compared to the tumor burden in the subject before or after treatment with the compound. As used herein, the term "tumor burden" refers to the total mass of tumor tissue in a subject with cancer.
[0052] In some embodiments, a "therapeutically effective amount" is an amount of a disclosed compound in monotherapy or combination therapy, i.e., an amount that, when administered in one or more doses, is effective to reduce the amount of radiation therapy required to observe tumor shrinkage in a subject by about 20%, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, or about 90% or more, compared to the amount of radiation therapy required to observe tumor shrinkage in a subject not treated with the compound.
[0053] Pharmaceutical Compositions
[0054] Pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers, or diluents, are readily available to one of ordinary skill in the art. Pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents, are readily available to one of ordinary skill in the art.
[0055] In some embodiments, the compounds of the present invention are formulated in an aqueous buffer. Suitable aqueous buffers include, but are not limited to, acetate, succinate, citrate, and phosphate buffers, which vary in strength from 5 to 1000 mM. In some embodiments, the aqueous buffer contains an agent that provides an isotonic solution. Such agents include, but are not limited to, sodium chloride, sugars, such as mannitol, dextrose, sucrose, and the like. In some embodiments, the aqueous buffer further contains a non-ionic surfactant, such as polysorbate 20 or 80. Optionally, the formulation may further contain a preservative. Suitable preservatives include, but are not limited to, benzyl alcohol, phenol, chlorobutanol, benzalkonium chloride, and the like. In other embodiments, the dosage form is stored at about 4° C. The formulations may also be lyophilized, which generally contain a cryoprotectant, such as sucrose, trehalose, lactose, maltose, and mannitol. Lyophilized formulations can be stored for long periods of time at room temperature.
[0056] As used herein, the pharmaceutical composition comprises or essentially consists of a compound disclosed in the present invention, or a pharma- ceutically acceptable salt thereof, an isomer thereof, or a tautomer thereof, and additionally, the pharmaceutical composition provides a pharmaceutical composition comprising or essentially consists of one or more additional active agents of interest. Any convenient active agent may be used in the present method together with the compound of the present invention. In one embodiment, the compound of the present invention and the immune checkpoint inhibitor, as well as the additional therapeutic agent as described in the present invention for combination therapy, are administered orally, subcutaneously, intramuscularly, intranasally, parenterally, or other routes. In another embodiment, the compound of the present invention and the chemotherapeutic agent (particularly a chemotherapeutic agent capable of inducing the production of cGAMP in vivo), and the additional therapeutic agent as described in the present invention for combination therapy, are administered orally, subcutaneously, intramuscularly, intranasally, parenterally, or other routes. The compound of the present invention and the second active agent (if present) are administered by the same or different routes of administration. Therapeutic agents are administered to the affected organ by any suitable means, including, but not limited to, oral, rectal, nasal, topical, vaginal, parenteral, intravenous, intranasal, or intratumoral injection.
[0057] The compounds of the present invention are administered in unit dosage form and can be prepared by any method well known to those skilled in the art. Such a method includes combining the compounds of the present invention with a pharma- ceutically acceptable carrier or diluent, which constitutes one of one or more auxiliary ingredients. The pharma- ceutically acceptable carrier is selected based on the selected route of administration and standard pharmaceutical practice. Each carrier must be "pharma- ceutically acceptable" in that it is compatible with the other ingredients of the formulation and does not cause harm to the subject or patient. The carrier may be solid or liquid, and the type is selected according to the type of administration commonly used.
[0058] Examples of suitable solid carriers include lactose, sucrose, gelatin, agar and bulk powders. Examples of suitable liquid carriers include water, pharma- ceutically acceptable fats and oils, alcohols or other organic solvents, such as esters, emulsions, syrups or elixirs, suspensions and solutions and / or suspensions reconstituted from non-effervescent granules. Such liquid carriers may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners and melting agents.
[0059] The present invention will be specifically described below.
[0060] One aspect of the present invention provides a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by the following chemical formula 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof:
[0061] [ka]
[0062] In the above Chemical Formula 1,
[0063] R1, R2 and R3 are each independently hydrogen; a hydroxyl group; a halogen group; 13 Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); ester group (-C(O)OR8); carboxylic acid group (-C(O)OH); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0064] A and B are each independently C6-C 10 Aryl group; C3-C 10Cyclyl group; C3-C 10 Heteroaryl groups; or C3-C 10 a heterocyclyl group;
[0065] R4, R5, R6 and R7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 13 Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0066] L a is hydrogen; hydroxyl group; halogen group; C1-C 13 Alkyl group; -Z a -Q3-E; or -Z a -Q1-M; a -Q1-M, where M is L b Ga-Z b -Q2, which is linked to Q2 to form a ring;
[0067] L b is hydrogen; hydroxyl group; halogen group; C1-C 13 Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl; amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or -Z b-Q2; and -Z b -Q2, where Q2 is L a Ga-Z a -Q1-M is linked to M to form a ring;
[0068] Said Z a or Z b may or may not exist independently, Z a or Z b If there is Z a or Z b are each independently -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2 )-, -C3-C 10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0069] Q1, Q2 and Q3 each independently represent -C n H n+2 -, -O(C n H n+2 )-, -(OC2H4) n -, -(C2H4O) n -, -(C n H n+2 )O-, -(C n H n+2 )CO-, -NR8(C n H n+2 )-, -(NR8C2H4) n -, -(C2H4NR8) n -, -(C n H n+2 )NR8-, -(C n H n+2 )O(C m H m+2 )-, -(C n H n+2 )O(C m H m+2 )CO-, -C3-C10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0070] The Q4 may be present or absent, and when present, -C n H n+2 -, -C n H n - or -C n H n-2 - and
[0071] The M is -O-, -CO-, -COO-, -C2H2-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2 )-, -NR8-; -NR8CH2-; -NHR8-; -NR8C(O)-; -NR8C(O)O-; -C(O)NR8-; -NR8C(O)NR8-; -NC(O)R8-; -NS(O)2R8-; -S(O)2-; -NR8S(O)2-; and -S(O)2NR8-;
[0072] The n and m each independently represent an integer of 0 to 15,
[0073] The E is [ka] or [ka] and
[0074] X2, X3 and X4 each independently represent a hydrogen atom; a halogen group; 13 Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0075] the X1 is present or absent, and if present, X1 is -CR8R9-, -O- or -NR8-;
[0076] The Y1, Y2, Y3 and Y4 each independently represent a C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; C3-C 10 Cyclyl group; or C3-C 10 a heterocyclyl group;
[0077] R8 and R9 are each independently hydrogen; a C1-C6 alkyl group; a C1-C6 alkenyl group; a C1-C6 alkynyl group; a C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; C3-C 10 Cyclyl group; C3-C 10 or R8, together with the nitrogen or carbon atom connected to R9, can optionally contain at least one of N, O, S, NH, C=N, C=O, -NHC(O)-, -NHC(O)NH-, -NHS(O)2-, or SO2, and can be selected from hydrogen, C1-C 13 Alkyl groups, C6-C 10 Aryl groups, C3-C 10 forming a 3- to 7-membered saturated ring optionally substituted with at least one of a heteroaryl group, a hydroxyl group, a halide group, and a cyano group;
[0078] The C1-C6 alkoxy group, C1-C 13 Alkyl group or C3-C 10 Cyclyl groups are hydrogen; hydroxyl; halogen; C1-C 13Alkyl group; C1-C6 alkoxy group; Amino group (-NR8R9); Nitro group (-N(O)2); Amide group (-(C=O)NR8R9); Carboxylic acid group (-C(O)OH); -Ester group (-C(O)OR8); Nitrile group (-CN); Urea group (-NR8(C=O)NR9-); Sulfonamide group (-NHS(O)2-); Sulfide group (-S-); Sulfone group (-S(O)2-); Phosphoryl group (-P(O)R8R9); C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0079] Said C6-C 10 Aryl groups, C3-C 10 Heteroaryl group or C3-C 10 A heterocyclyl group is a group selected from the group consisting of hydrogen, hydroxyl, halogen, carbonyl (-(C=O)R8R9), halogen or C3-C 10 C1-C3 alkyl groups substituted or unsubstituted with heterocyclyl groups; halogen or C3-C 10 C1-C3 alkoxy groups, substituted or unsubstituted with heterocyclyl groups; C6-C 10 Phenoxy; Amino group (-NR8R9); Amide group (-(C=O)NR8R9); C6-C 10 Aryl group; C3-C 10 Heteroaryl groups and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0080] Said C3-C 10 Heteroaryl groups and C3-C 10 The heterocyclyl group contains one or more heteroatoms selected from the group consisting of N, O, and S.
[0081] In one aspect of the present invention, there is provided a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1, wherein A and B are each independently furan, benzofuran, pyrrole, indole, thiophene, benzothiophene, imidazole, benzimidazole, purine, pyrazole, indazole, oxazole, benzoxazole, thiazole, benzothiazole, benzene, naphthalene, anthracene, pyridine, quinoline, pyrazine, quinoxaline, acridine, pyrimidine, quinazoline, pyridazine, cinnoline, phthalazine, or triazine, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.
[0082] In one aspect of the present invention, A and B are each independently benzene, pyrazole, pyridine, indazole, pyrimidine, quinoline, or thiazolyl, and R1, R2, and R3 are each independently hydrogen, a halogen group, a C1-C 13 Alkyl group or C3-C 10 Provided is a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by chemical formula 1, which is a cyclyl group, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0083] In one aspect of the present invention, R4, R5, R6 and R7 are each independently selected from the group consisting of hydrogen, a hydroxyl group, a halogen group, -NHCH3, -NHMs, -CO(NH)CH3, -OCH3, -OC2H5, and -OC6H. 12 The present invention provides a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by the chemical formula 1, wherein R is O, R is O, and R is O.
[0084] In one aspect of the present invention, the compound is represented by the following formula 2:
[0085] [ka]
[0086] In the above Chemical Formula 2,
[0087] R1, R2 and R3 are each independently hydrogen; a hydroxyl group; a halogen group; 13 Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); ester group (-C(O)OR8); carboxylic acid group (-C(O)OH); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0088] A and B are each independently C6-C 10 Aryl group; C3-C 10 Cyclyl group; C3-C 10 Heteroaryl groups; or C3-C 10 a heterocyclyl group;
[0089] R4, R5, R6 and R7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 13 Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0090] L b is hydrogen; hydroxyl group; halogen group; C1-C 13Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); or sulfone group (-S(O)2R8);
[0091] Said Z a -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2 )-, -C3-C 10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0092] The Q3 is -C n H n+2 -, -O(C n H n+2 )-, -(OC2H4)n-, -(C2H4O) n -, -(C n H n+2 )O-, -(C n H n+2 )CO-, -NR8(C n H n+2 )-, -(NR8C2H4)n-, -(C2H4NR8) n -, -(C n H n+2 )NR8-, -(C n H n+2 )O(C m H m+2 )-, -(C n H n+2 )O(C m H m+2 )CO-, -C3-C10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0093] The Q4 may be present or absent, and when present, -C n H n+2 -, -C n H n - or -C n H n-2 - and
[0094] The n and m each independently represent an integer of 0 to 15,
[0095] The E is [ka] or [ka] and
[0096] X2, X3 and X4 each independently represent a hydrogen atom; a halogen group; 13 Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0097] the X1 is present or absent, and if present, X1 is -CR8R9-, -O- or -NR8-;
[0098] The Y1, Y2, Y3 and Y4 each independently represent a C6-C 10 Aryl group; C3-C10 Heteroaryl groups; C3-C 10 Cyclyl group; or C3-C 10 a heterocyclyl group;
[0099] R8 and R9 are each independently hydrogen; a C1-C6 alkyl group; a C1-C6 alkenyl group; a C1-C6 alkynyl group; a C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; C3-C 10 Cyclyl group; C3-C 10 or R8, together with the nitrogen or carbon atom connected to R9, can optionally contain at least one of N, O, S, NH, C=N, C=O, -NHC(O)-, -NHC(O)NH-, -NHS(O)2-, or SO2, and can be selected from hydrogen, C1-C 13 Alkyl groups, C6-C 10 Aryl groups, C3-C 10 forming a 3- to 7-membered saturated ring optionally substituted with at least one of a heteroaryl group, a hydroxyl group, a halide group, and a cyano group;
[0100] The C1-C6 alkoxy group, C1-C 13 Alkyl group or C3-C 10 Cyclyl groups are hydrogen; hydroxyl; halogen; C1-C 13 Alkyl group; C1-C6 alkoxy group; Amino group (-NR8R9); Nitro group (-N(O)2); Amide group (-(C=O)NR8R9); Carboxylic acid group (-C(O)OH); -Ester group (-C(O)OR8); Nitrile group (-CN); Urea group (-NR8(C=O)NR9-); Sulfonamide group (-NHS(O)2-); Sulfide group (-S-); Sulfone group (-S(O)2-); Phosphoryl group (-P(O)R8R9); C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0101] Said C6-C 10 Aryl groups, C3-C 10Heteroaryl group or C3-C 10 A heterocyclyl group is a group selected from the group consisting of hydrogen, hydroxyl, halogen, carbonyl (-(C=O)R8R9), halogen or C3-C 10 C1-C3 alkyl groups substituted or unsubstituted with heterocyclyl groups; halogen or C3-C 10 C1-C3 alkoxy groups, substituted or unsubstituted with heterocyclyl groups; C6-C 10 Phenoxy; Amino group (-NR8R9); Amide group (-(C=O)NR8R9); C6-C 10 Aryl group; C3-C 10 Heteroaryl groups and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0102] Said C3-C 10 Heteroaryl groups and C3-C 10 The heterocyclyl group is a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by chemical formula 1, which contains one or more heteroatoms selected from the group consisting of N, O, and S, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0103] In one embodiment, in Formula 2, A and B are each independently benzene, pyrazole, pyridine, indazole, pyrimidine, quinoline, or thiazolyl; R1, R2, and R3 are each independently hydrogen, a halogen group, C1-C 13 Alkyl group or C3-C 10 a cyclyl group, wherein R4, R5, R6 and R7 are each independently hydrogen; a hydroxyl group; a halogen group; -NHCH3; -NHMs; -CO(NH)CH3; -OCH3; -OC2H5; or -OC6H 12 COOCH3; and Y1 is [ka] and Y a and Y b are each independently hydrogen; halogen; C1-C 13Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl; amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9); and Y c and Y d are each independently -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2 )-, -C3-C 10 Cyclyl group -; or -C3-C 10 a heterocyclyl group, -; and Y e is C6-C 10 Aryl group; C3-C 10 Cyclyl group; C3-C 10 Heteroaryl groups; or C3-C 10 The present invention provides a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by the chemical formula 1, wherein R is a heterocyclyl group; a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0104] In one embodiment, in Formula 2, E is E1, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11, E12, E13, E14, or E15:
[0105] [ka]
[0106] Provided is a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by chemical formula 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0107] In one embodiment, in Formula 2,
[0108] Q3 is any one of -(CH2)n-, -(OC2H4)n-, -(CH2)nCO-, n is an integer, A and B are each any one or more of a heteroaryl ring, a cyclic hydrocarbon, and an alkyl group, said n being an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, said heteroaryl ring is any one of phenyl, substituted phenyl, pyrazole, and substituted indole, and said cyclic hydrocarbon is any one or more of piperazine and piperidine, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.
[0109] In one aspect of the present invention, the compound is represented by the following formula 3:
[0110] [ka]
[0111] In the above Chemical Formula 3,
[0112] R1, R2 and R3 are each independently hydrogen; a hydroxyl group; a halogen group; 13 Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); ester group (-C(O)OR8); carboxylic acid group (-C(O)OH); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0113] A and B are each independently C6-C 10 Aryl group; C3-C 10 Cyclyl group; C3-C 10 Heteroaryl groups; or C3-C 10 a heterocyclyl group;
[0114] R4, R5, R6 and R7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 13 Alkyl group; C1-C6 alkoxy group; C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0115] Said Z a or Z b are each independently -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2 )-, -C3-C 10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0116] Q1 and Q2 each independently represent -C n H n+2 -, -O(C n H n+2 )-, -(OC2H4) n -, -(C2H4O) n -, -(C n H n+2 )O-, -(C n H n+2 )CO-, -NR8(C n H n+2 )-, -(NR8C2H4) n -, -(C2H4NR8) n -, -(C n H n+2 )NR8-, -(C n H n+2 )O(C m H m+2 )-, -(C n H n+2 )O(C m H m+2 )CO-, -C3-C 10 Cyclyl group -; or -C3-C 10 a heterocyclyl group -;
[0117] The M is -O-, -CO-, -COO-, -C2H2-, -C n H n+2 -, -O(C n H n+2 )-, -(C n H n+2 )O-, -(C n H n+2 )O(C m H m+2 )-, -NR8-; -NR8CH2-; -NHR8-; -NR8C(O)-; -NR8C(O)O-; -C(O)NR8-; -NR8C(O)NR8-; -NC(O)R8-; -NS(O)2R8-; -S(O)2-; -NR8S(O)2-; and -S(O)2NR8-;
[0118] The E is [ka] or [ka] and
[0119] X2, X3 and X4 each independently represent a hydrogen atom; a halogen group; 13 Alkyl group;C1-C6 haloalkyl group;C1-C6 alkoxy group;C3-C 10 Cyclyl group; C3-C 10 Heterocyclyl group; -C(O)-(C1-C 13 alkyl); amino group (-NR8R9); nitro group (-N(O)2); amide group (-(C=O)NR8R9); carboxylic acid group (-C(O)OH); ester group (-C(O)OR8); nitrile group (-CN); sulfonamide group (-NHS(O)2R8); sulfide group (-SR8); sulfone group (-S(O)2R8); or phosphoryl group (-P(O)R8R9);
[0120] the X1 is present or absent, and if present, X1 is -CR8R9-, -O- or -NR8-;
[0121] The Y1, Y2, Y3 and Y4 each independently represent a C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; C3-C 10 Cyclyl group; or C3-C 10 a heterocyclyl group;
[0122] The n and m each independently represent an integer of 0 to 15,
[0123] R8 and R9 are each independently hydrogen; a C1-C6 alkyl group; a C1-C6 alkenyl group; a C1-C6 alkynyl group; a C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; C3-C 10 Cyclyl group; C3-C 10or R8, together with the nitrogen or carbon atom connected to R9, can optionally contain at least one of N, O, S, NH, C=N, C=O, -NHC(O)-, -NHC(O)NH-, -NHS(O)2-, or SO2, and can be selected from hydrogen, C1-C 13 Alkyl groups, C6-C 10 Aryl groups, C3-C 10 forming a 3- to 7-membered saturated ring optionally substituted with at least one of a heteroaryl group, a hydroxyl group, a halide group, and a cyano group;
[0124] The C1-C6 alkoxy group, C1-C 13 Alkyl group or C3-C 10 Cyclyl groups are hydrogen; hydroxyl; halogen; C1-C 13 Alkyl group; C1-C6 alkoxy group; Amino group (-NR8R9); Nitro group (-N(O)2); Amide group (-(C=O)NR8R9); Carboxylic acid group (-C(O)OH); -Ester group (-C(O)OR8); Nitrile group (-CN); Urea group (-NR8(C=O)NR9-); Sulfonamide group (-NHS(O)2-); Sulfide group (-S-); Sulfone group (-S(O)2-); Phosphoryl group (-P(O)R8R9); C6-C 10 Aryl group; C3-C 10 Heteroaryl groups; and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0125] Said C6-C 10 Aryl groups, C3-C 10 Heteroaryl group or C3-C 10 A heterocyclyl group is a group selected from the group consisting of hydrogen, hydroxyl, halogen, carbonyl (-(C=O)R8R9), halogen or C3-C 10 C1-C3 alkyl groups substituted or unsubstituted with heterocyclyl groups; halogen or C3-C 10 C1-C3 alkoxy groups, substituted or unsubstituted with heterocyclyl groups; C6-C 10 Phenoxy; Amino group (-NR8R9); Amide group (-(C=O)NR8R9); C6-C 10Aryl group; C3-C 10 Heteroaryl groups and C3-C 10 one or more substituents selected from the group consisting of heterocyclyl groups;
[0126] Said C3-C 10 Heteroaryl groups and C3-C 10 The heterocyclyl group provides a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by formula 1, which contains one or more heteroatoms selected from the group consisting of N, O, and S, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0127] In one embodiment, in Formula 3, A and B are each independently benzene, pyrazole, pyridine, indazole, pyrimidine, quinoline, or thiazolyl; R1, R2, and R3 are each independently hydrogen, a halogen group, C1-C 13 Alkyl group or C3-C 10 a cyclyl group, wherein R4, R5, R6 and R7 are each independently hydrogen; a hydroxyl group; a halogen group; -NHCH3; -NHMs; -CO(NH)CH3; -OCH3; -OC2H5; or -OC6H 12 The present invention provides a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by the chemical formula 1, wherein R is O, R is O, and R is O.
[0128] In one embodiment, in Formula 3, E is any one of the following E1, E2, E3, E4, E5, E6, E7, E8, E9, E 10 , E 11 , E 12 , E 13 , E 14 or E 15 is
[0129] [ka]
[0130] Provided is a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by chemical formula 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0131] In one embodiment, in Formula 3, Q1 and Q2 are each -(CH2) n -, -O(CH2) n -, -N(CH2) n - and -NH(CH2) n -, n is an integer, A and B are each any one of a heteroaryl ring, a cyclic hydrocarbon, and an alkyl group, and M is -CHCH-, -CH2CH2-, -NHCO-, -CONH-, -NMe-, -NAc-, -NMs-, -NHCONHR 10 -,-NHCOR 10 -,-NHSONR 10 - and -O-, where R 10 is any one of an alkyl group, a cyclic hydrocarbon, a phenyl group, and a substituted phenyl group, said n being an integer of 0, 1, 2, 3, or 4, said heteroaryl ring is any one of phenyl, pyridine, substituted phenyl, and pyrazole, and said cyclic hydrocarbon is any one or more of piperazine and cyclohexane, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.
[0132] In one aspect of the present invention, there is provided a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1, characterized in that the compound is selected from the group consisting of the following compound numbers 1 to 126, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof:
[0133] (Compound No. 1)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0134] (Compound No. 2)(2 1 Z,4 4 E)-8-Methyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0135] (Compound No. 3) 1-((2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethan-1-one;
[0136] (Compound No. 4) 1-((2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)butan-1-one;
[0137] (Compound No. 5)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(4-chlorophenyl)methanone;
[0138] (Compound No. 6)(2 1 Z,4 4 E) -N-Cyclohexyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide;
[0139] (Compound No. 7)(2 1 Z,4 4 E) -N-(3-methoxyphenyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide;
[0140] (Compound No. 8)(2 1 Z,4 4 E) -N-Ethyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide;
[0141] (Compound No. 9)(2 1 Z,4 4 E)-8-(Methylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0142] (Compound No. 10)(2 1 Z,4 4 E)-8-((3,4-difluorophenyl)sulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0143] (Compound No. 11)(2 1 Z,4 4 E)-8-(phenylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0144] (Compound No. 12)(21 Z,4 4 E)-8-(Cyclopropylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0145] (Compound No. 13)(2 1 Z,4 4 E)-8-(propylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0146] (Compound No. 14)(2 1 Z,4 4 E)-8-((5-chlorothiophene-2-yl)sulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0147] (Compound No. 15)(2 1 Z,4 4 E)-8-(Cyclohexylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0148] (Compound No. 16) (Z)-5-oxa-3,9,15-triazine-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0149] (Compound No. 17)(1 4 Z,2 1 Z)-1 1H-5-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1(4,1)-pyrazolac-4(1,4)-benzenecyclohexadecapan-10-one;
[0150] (Compound No. 18)(1 4 Z,2 1 Z,4 4 E)-1 1 H, 4 1 H-3,8-Diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(4,1)-dipyrazolacylopentadecapan-9-one;
[0151] (Compound No. 19)(1 4 Z,2 1 Z)-1 1 H-3-Aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1(4,1)-pyrazolac-4(1,4)-benzenecyclododecapane-9-one;
[0152] (Compound No. 20) (Z)-13-Fluoro-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one;
[0153] (Compound No. 21)(2 1 Z,4 4 E)-13-Fluoro-4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclohexadecapan-9-one;
[0154] (Compound No. 22)(Z)-1 3 -fluoro-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one;
[0155] (Compound No. 23) (Z)-17-oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one;
[0156] (Compound No. 24) (Z)-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one;
[0157] (Compound No. 25)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecapan-6-one;
[0158] (Compound No. 26)(2 1 Z,4 4 E)-4 1 H-15-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazo-1(1,4)-benzenecyclopentadecapan-10-one;
[0159] (Compound No. 27)(2 1 Z,4 4 E)-4 1 H-17-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazo-1(1,4)-benzenecycloheptadecapan-10-one;
[0160] (Compound No. 28) (Z)-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0161] (Compound No. 29) (Z)-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one;
[0162] (Compound No. 30) (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecaffeine;
[0163] (Compound No. 31) (Z)-1-(5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl)propan-1-one;
[0164] (Compound No. 32) (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl(4-chlorophenyl)methanone;
[0165] (Compound No. 33)(2 1 Z,7Z)-5,10-dioxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclodecapan-7-ene;
[0166] (Compound No. 34)(Z)-4 2 -Methoxy-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0167] (Compound No. 35)(2 1 Z,4 4 E)-4 1 H-11,14-dioxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecyclotetradecapan-9-one;
[0168] (Compound No. 36)(2 1 Z,4 4 E)-4 1 H-14-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclotetradecapan-9-one;
[0169] (Compound No. 37)(2 1 Z,4 4 E)-4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclohexadecapan-9-one;
[0170] (Compound No. 38) (Z)-5,15-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0171] (Compound No. 39) N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0172] (Compound No. 40) N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)propyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0173] (Compound No. 41) N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0174] (Compound No. 42) N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0175] (Compound No. 43) N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0176] (Compound No. 44) N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)butyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0177] (Compound No. 45) N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0178] (Compound No. 46) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0179] (Compound No. 47) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0180] (Compound No. 48) N-(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0181] (Compound No. 49) N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0182] (Compound No. 50) N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0183] (Compound No. 51) N-(3-(2-((4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0184] (Compound No. 52) N-(3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0185] (Compound No. 53) 3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-N-methylbenzamide;
[0186] (Compound No. 54) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-phenylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione;
[0187] (Compound No. 55) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione;
[0188] (Compound No. 56) 4-((9-(4-(4-((7-(1H-indol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0189] (Compound No. 57) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(4-hydroxyphenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione;
[0190] (Compound No. 58) methyl-7-(4-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)heptanoate;
[0191] (Compound No. 59) N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0192] (Compound No. 60) N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0193] (Compound No. 61) N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0194] (Compound No. 62) N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0195] (Compound No. 63) N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0196] (Compound No. 64) N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0197] (Compound No. 65) N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0198] (Compound No. 66) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0199] (Compound No. 67) N-(3-(2-((4-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0200] (Compound No. 68) N-(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0201] (Compound No. 69) N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0202] (Compound No. 70) N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0203] (Compound No. 71) N-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0204] (Compound No. 72) N-(3-(2-((6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0205] (Compound No. 73) N-(3-(2-((6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0206] (Compound No. 74) N-(3-(2-((6-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0207] (Compound No. 75) N-(3-(2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0208] (Compound No. 76) N-(3-(2-((6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0209] (Compound No. 77) N-(3-(2-((6-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0210] (Compound No. 78) N-(3-(2-((6-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0211] (Compound No. 79) N-(3-(2-((6-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0212] (Compound No. 80) N-(3-(2-((6-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0213] (Compound No. 81) N-(3-(2-((6-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0214] (Compound No. 82) N-(3-(2-((6-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0215] (Compound No. 83) (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetamino)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide;
[0216] (Compound No. 84) (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide;
[0217] (Compound No. 85) (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide;
[0218] (Compound No. 86) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0219] (Compound No. 87) 4-((5-(4-(5-((7-(3,5-difluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0220] (Compound No. 88) 4-((5-(4-(5-((7-(2-aminopyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0221] (Compound No. 89) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(quinolin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0222] (Compound Number 90) tert-butyl 4-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)benzyl)piperazine-1-carboxylate;
[0223] (Compound No. 91) (E)-2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-styrylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0224] (Compound Number 92) tert-butyl 4-(4-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate;
[0225] (Compound No. 93) 4-((5-(4-(5-((7-(4-(dimethylamino)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0226] (Compound No. 94) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(pyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0227] (Compound No. 95) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(thiazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0228] (Compound No. 96) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0229] (Compound No. 97) 4-((5-(4-(5-((7-((3,5-difluorophenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0230] (Compound No. 98) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-((3-methoxyphenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)aminopyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0231] (Compound No. 99) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0232] (Compound No. 100) N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide;
[0233] (Compound No. 101) N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide;
[0234] (Compound No. 102) N-(3-(2-((4-(4-(2-(2-(3-(4-(4-(3-(2,4-dihydroxy-5-isophenylpropyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0235] (Compound No. 103) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0236] (Compound No. 104) N-(3-(2-((4-(4-(2-(2-(3-(4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0237] (Compound No. 105) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0238] (Compound No. 106) 2-amino-4-(2,4-dichloro-5-(2-(4-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide;
[0239] (Compound No. 107) N-(3-(2-((4-(4-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0240] (Compound No. 108) N-(3-(2-((4-(4-(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0241] (Compound No. 109) 4-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0242] (Compound No. 110) 4-(3-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)propoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0243] (Compound No. 111) 4-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione;
[0244] (Compound No. 112) 4-((6-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)hexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0245] (Compound No. 113) 4-((8-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)octyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0246] (Compound No. 114) 4-((8-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)octyl)oxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione;
[0247] (Compound No. 115) 4-((11-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)undecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0248] (Compound No. 116) 4-((9-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dioneundecaffeine;
[0249] (Compound No. 117) 5-(4-((1-(3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione;
[0250] (Compound No. 118) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)propanamide;
[0251] (Compound No. 119) 3-(2-(2-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)propanamide;
[0252] (Compound No. 120) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)propan-1-one;
[0253] (Compound No. 121) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one;
[0254] (Compound No. 122) 3-(2-(2-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)propan-1-one;
[0255] (Compound No. 123) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one;
[0256] (Compound No. 124) 4-(5-(2-(4-(3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)-2,4-dichlorophenyl)-2-amino-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide;
[0257] (Compound No. 125)(2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)phenyl)methanone; and
[0258] (Compound No. 126)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidin-4-yl)methanone.
[0259] In one aspect of the present invention, there is provided a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein the pharma-ceutically acceptable salt is a salt of an inorganic or organic acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.
[0260] Another aspect of the present invention provides a pharmaceutical composition for preventing, alleviating or treating cancer, comprising any one of the compounds according to the above aspects of the present invention as an active ingredient.
[0261] In another aspect of the present invention, there is provided a pharmaceutical composition for preventing, alleviating or treating cancer, a disease caused by abnormal cell growth due to protein kinase activity.
[0262] In another aspect of the present invention, the compound provides a pharmaceutical composition for preventing, alleviating or treating cancer, which has an inhibitory activity against a protein kinase of 80% or more at 1 uM.
[0263] In another aspect of the invention, the protein kinase is selected from the group consisting of ABL1, ABL2, ALK, ARK5, Aurora A, Aurora B, Aurora C, AXL, BLK, BMX, BRK, c-Kit, c-MER, c-Src, CAMK2a, CAMK2d, CDK16, CDK17, CDK18, CDK2 / cyclin A, CDK2 / cyclin O, CDK4 / cyclin D1, CDK4 / cyclin D2, CDK4 / cyclin D3, CDK6 / cyclin D1, CDK6 / cyclin D3, CDK7 / cyclin H, CDK9 / cyclin K, CDK9 / cyclin T1, CDK9 / cyclin T2, CK2a, CK2a2, CLK1, CLK2, CLK4, DAPK1, DAPK2, DDR1, DDR2, DRAK1, DYRK1 / DYRK1A, DYRK1B, DYRK3, EPHA1, EPHA2, EPHA4, EPH A5, EPHA6, EPHA7, EPHB1, EPHB2, ERBB4 / HER4, ERK7 / MAPK15, ERN2 / IRE2, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGR, F LT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GLK / MAP4K3, GSK3a, HIPK2, HIPK3, HIPK4, HPK1 / MAP4K1, IGF1R, IKKe / I KBKE, IR, IRAK1, IRR / INSRR, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LCK, LIMK1, LIMK2, LRRK2, LYN, LYNB, MAK, MARK1, MARK2 / PAR-1Ba, MARK3, MARK4, MAST3, MEKK2, MELK, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, MYLK4, NEK1, NEK2, NEK5, NEK9, p 70S6K / RPS6KB1, PAK4, PAK5, PAK6, PDGFRa, PDGFRb, PHKg1, PHKg2, PKAcb, PKCa, PKCb2, PKCg, PKCmu / PRKD1, PKCnu / PRKD3, PKD2 / PRKD2, PKN1 / PRK1, PLK4 / SAK, PRKX, P The present invention provides a pharmaceutical composition for preventing, alleviating or treating cancer, the cancer being any one or more of YK2, RET, ROS / ROS1, RSK2, RSK3, RSK4, SIK1, SIK2, SLK / STK2, SNARK / NUAK2, STK16, STK22D / TSSK1, STK33, STK38 / NDR1, STK38L / NDR2, STK39 / STLK3, SYK, TBK1, TEC, TIE2 / TEK, TLK2, TNK1, TRKA, TRKB, TRKC, TYK2, TYRO3 / SKY, ULK1, ULK2, ULK3, WEE1, YES / YES1, YSK4 / MAP3K19 and ZIPK / DAPK3.
[0264] In another aspect of the present invention, there is provided a pharmaceutical composition for preventing, alleviating or treating cancer, wherein the disease is selected from the group consisting of gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenoma, uterine cancer, cervical cancer, head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, neointestinal cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer such as leukemia, multiple myeloma, myelodysplastic syndrome, lymphoma such as Hodgkin's disease and non-Hodgkin's lymphoma, and fibroadenoma.
[0265] The manufacturing method of the present invention is as follows.
[0266] The pharma- ceutically acceptable salts of the 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds represented by Formula 1 according to the present invention can be prepared by methods commonly known in the art. The pharma- ceutically acceptable salts have low toxicity to the human body and should not adversely affect the biological activity and physicochemical properties of the parent compound. The pharma- ceutical acceptable salts include pharma- ceutical free acids and acid addition salts of the base compounds represented by Formula 1, alkali metal salts (such as sodium salts) and alkaline earth metal salts (such as calcium salts), organic salts and organic base addition salts of the carboxylic acids represented by Formula 1, and amino acid addition salts. The free acids used in the preparation of the pharma- ceutical acceptable salts are divided into inorganic acids and organic acids. Examples of inorganic acids include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, and bromic acid. Examples of organic acids that can be used include acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, oxalic acid, benzoic acid, embonic acid, aspartic acid, and glutamic acid. Examples of organic bases that can be used to prepare organic base addition salts include tris(hydroxymethyl)methylamine and dicyclohexylamine. Examples of amino acids that can be used to prepare amino acid addition salts include natural amino acids such as alanine and glycine.
[0267] The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by formula 1 according to the present invention includes all hydrates and solvates, together with the pharma- ceutically acceptable salts. The hydrates and solvates are obtained by dissolving the 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by formula 1 in a water-miscible solvent such as methanol, ethanol, acetone, or 1,4-dioxane, followed by adding a free acid or free base, followed by crystallization or recrystallization. In such a case, a solvate (particularly a hydrate) may be formed. Therefore, the compounds of the present invention include stoichiometric solvates, including hydrates, in addition to compounds containing various amounts of water that can be prepared by methods such as lyophilization.
[0268] The substituents used to define the compounds according to the present invention are explained in more detail below.
[0269] In the present invention, the term "halogen atom" means a fluorine, chlorine, bromine or iodine atom.
[0270] As used herein, "alkyl group" refers to an aliphatic saturated hydrocarbon group having from 1 to 6 carbon atoms, including methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, i-butyl, t-butyl, cyclobutyl, cyclopropylmethyl, n-pentyl, i-pentyl, neopentyl, t-pentyl, cyclopentyl, cyclobutylmethyl, n-hexyl, i-hexyl, cyclohexyl, cyclopentylmethyl, and the like.
[0271] By "haloalkyl group" in the present invention is meant an alkyl group in which one or more hydrogen atoms have been substituted by halogen atoms, such as a trifluoromethyl group.
[0272] The term "alkoxy group" as used herein means a hydroxy group in which the hydrogen atom is replaced by a substituent selected from the group consisting of alkyl groups of CC, including methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, and t-butoxy.
[0273] In the present invention, the term "heteroaryl group" refers to a monocyclic, bicyclic, or tricyclic aromatic heterohydrocarbon group containing one or more heteroatoms, including pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazolyl, indolyl, isoindolyl, benzofuranyl, benzofurazanyl, dibenzofuranyl, isobenzofuranyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, dibenzothiophenyl, naphthyridine, benzisothiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, phthalazinyl, tinolinyl, quinazolinyl, and the like.
[0274] In the present invention, the term "heterocyclic group" refers to a heterohydrocarbon ring group containing one or more heteroatoms, including a morpholinyl group, a piperidine group, a piperazinyl group, an N-protected piperazinyl group, and the like.
[0275] More specific examples of the 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine cyclized compound represented by Formula 1 as described above are as follows.
[0276] (Compound No. 1)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0277] (Compound No. 2)(2 1 Z,4 4 E)-8-Methyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0278] (Compound No. 3) 1-((2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethan-1-one;
[0279] (Compound No. 4) 1-((2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)butan-1-one;
[0280] (Compound No. 5)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(4-chlorophenyl)methanone;
[0281] (Compound No. 6)(2 1 Z,4 4 E) -N-Cyclohexyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide;
[0282] (Compound No. 7)(2 1 Z,4 4 E) -N-(3-methoxyphenyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide;
[0283] (Compound No. 8)(21 Z,4 4 E) -N-Ethyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide;
[0284] (Compound No. 9)(2 1 Z,4 4 E)-8-(Methylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0285] (Compound No. 10)(2 1 Z,4 4 E)-8-((3,4-difluorophenyl)sulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0286] (Compound No. 11)(2 1 Z,4 4 E)-8-(phenylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0287] (Compound No. 12)(2 1 Z,4 4 E)-8-(Cyclopropylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0288] (Compound No. 13)(2 1 Z,4 4E)-8-(propylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0289] (Compound No. 14)(2 1 Z,4 4 E)-8-((5-chlorothiophene-2-yl)sulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0290] (Compound No. 15)(2 1 Z,4 4 E)-8-(Cyclohexylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine;
[0291] (Compound No. 16) (Z)-5-oxa-3,9,15-triazine-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0292] (Compound No. 17)(1 4 Z,2 1 Z)-1 1 H-5-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1(4,1)-pyrazolac-4(1,4)-benzenecyclohexadecapan-10-one;
[0293] (Compound No. 18)(1 4 Z,2 1 Z,4 4 E)-1 1 H, 4 1H-3,8-Diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(4,1)-dipyrazolacylopentadecapan-9-one;
[0294] (Compound No. 19)(1 4 Z,2 1 Z)-1 1 H-3-Aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1(4,1)-pyrazolac-4(1,4)-benzenecyclododecapane-9-one;
[0295] (Compound No. 20) (Z)-13-Fluoro-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one;
[0296] (Compound No. 21)(2 1 Z,4 4 E)-13-Fluoro-4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclohexadecapan-9-one;
[0297] (Compound No. 22)(Z)-1 3 -fluoro-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one;
[0298] (Compound No. 23) (Z)-17-oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one;
[0299] (Compound No. 24) (Z)-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one;
[0300] (Compound No. 25)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecapan-6-one;
[0301] (Compound No. 26)(2 1 Z,4 4 E)-4 1 H-15-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazo-1(1,4)-benzenecyclopentadecapan-10-one;
[0302] (Compound No. 27)(2 1 Z,4 4 E)-4 1 H-17-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazo-1(1,4)-benzenecycloheptadecapan-10-one;
[0303] (Compound No. 28) (Z)-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0304] (Compound No. 29) (Z)-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one;
[0305] (Compound No. 30) (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecaffeine;
[0306] (Compound No. 31) (Z)-1-(5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl)propan-1-one;
[0307] (Compound No. 32) (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl(4-chlorophenyl)methanone;
[0308] (Compound No. 33)(2 1 Z,7Z)-5,10-dioxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclodecapan-7-ene;
[0309] (Compound No. 34)(Z)-4 2 -Methoxy-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0310] (Compound No. 35)(2 1 Z,4 4 E)-4 1 H-11,14-dioxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecyclotetradecapan-9-one;
[0311] (Compound No. 36): (2 1 Z,4 4 E)-4 1H-14-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclotetradecapan-9-one;
[0312] (Compound No. 37)(2 1 Z,4 4 E)-4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclohexadecapan-9-one;
[0313] (Compound No. 38) (Z)-5,15-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one;
[0314] (Compound No. 39) N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0315] (Compound No. 40) N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)propyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0316] (Compound No. 41) N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0317] (Compound No. 42) N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0318] (Compound No. 43) N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0319] (Compound No. 44) N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)butyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0320] (Compound No. 45) N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0321] (Compound No. 46) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0322] (Compound No. 47) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0323] (Compound No. 48) N-(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0324] (Compound No. 49) N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0325] (Compound No. 50) N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0326] (Compound No. 51) N-(3-(2-((4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0327] (Compound No. 52) N-(3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0328] (Compound No. 53) 3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-N-methylbenzamide;
[0329] (Compound No. 54) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-phenylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione;
[0330] (Compound No. 55) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione;
[0331] (Compound No. 56) 4-((9-(4-(4-((7-(1H-indol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0332] (Compound No. 57) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(4-hydroxyphenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione;
[0333] (Compound No. 58) methyl-7-(4-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)heptanoate;
[0334] (Compound No. 59) N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0335] (Compound No. 60) N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0336] (Compound No. 61) N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0337] (Compound No. 62) N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0338] (Compound No. 63) N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0339] (Compound No. 64) N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0340] (Compound No. 65) N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0341] (Compound No. 66) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0342] (Compound No. 67) N-(3-(2-((4-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0343] (Compound No. 68) N-(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0344] (Compound No. 69) N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0345] (Compound No. 70) N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0346] (Compound No. 71) N-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0347] (Compound No. 72) N-(3-(2-((6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0348] (Compound No. 73) N-(3-(2-((6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0349] (Compound No. 74) N-(3-(2-((6-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0350] (Compound No. 75) N-(3-(2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0351] (Compound No. 76) N-(3-(2-((6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0352] (Compound No. 77) N-(3-(2-((6-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0353] (Compound No. 78) N-(3-(2-((6-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0354] (Compound No. 79) N-(3-(2-((6-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0355] (Compound No. 80) N-(3-(2-((6-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0356] (Compound No. 81) N-(3-(2-((6-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0357] (Compound No. 82) N-(3-(2-((6-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0358] (Compound No. 83) (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetamino)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide;
[0359] (Compound No. 84) (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide;
[0360] (Compound No. 85) (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide;
[0361] (Compound No. 86) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0362] (Compound No. 87) 4-((5-(4-(5-((7-(3,5-difluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0363] (Compound No. 88) 4-((5-(4-(5-((7-(2-aminopyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0364] (Compound No. 89) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(quinolin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0365] (Compound Number 90) tert-butyl 4-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)benzyl)piperazine-1-carboxylate;
[0366] (Compound No. 91) (E)-2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-styrylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0367] (Compound Number 92) tert-butyl 4-(4-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate;
[0368] (Compound No. 93) 4-((5-(4-(5-((7-(4-(dimethylamino)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0369] (Compound No. 94) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(pyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0370] (Compound No. 95) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(thiazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0371] (Compound No. 96) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0372] (Compound No. 97) 4-((5-(4-(5-((7-((3,5-difluorophenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0373] (Compound No. 98) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-((3-methoxyphenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)aminopyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione;
[0374] (Compound No. 99) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0375] (Compound No. 100) N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide;
[0376] (Compound No. 101) N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide;
[0377] (Compound No. 102) N-(3-(2-((4-(4-(2-(2-(3-(4-(4-(3-(2,4-dihydroxy-5-isophenylpropyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0378] (Compound No. 103) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0379] (Compound No. 104) N-(3-(2-((4-(4-(2-(2-(3-(4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0380] (Compound No. 105) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0381] (Compound No. 106) 2-amino-4-(2,4-dichloro-5-(2-(4-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide;
[0382] (Compound No. 107) N-(3-(2-((4-(4-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0383] (Compound No. 108) N-(3-(2-((4-(4-(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0384] (Compound No. 109) 4-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0385] (Compound No. 110) 4-(3-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)propoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0386] (Compound No. 111) 4-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione;
[0387] (Compound No. 112) 4-((6-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)hexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0388] (Compound No. 113) 4-((8-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)octyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0389] (Compound No. 114) 4-((8-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)octyl)oxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione;
[0390] (Compound No. 115) 4-((11-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)undecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0391] (Compound No. 116) 4-((9-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dioneundecaffeine;
[0392] (Compound No. 117) 5-(4-((1-(3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione;
[0393] (Compound No. 118) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)propanamide;
[0394] (Compound No. 119) 3-(2-(2-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)propanamide;
[0395] (Compound No. 120) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)propan-1-one;
[0396] (Compound No. 121) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one;
[0397] (Compound No. 122) 3-(2-(2-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)propan-1-one;
[0398] (Compound No. 123) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one;
[0399] (Compound No. 124) 4-(5-(2-(4-(3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)-2,4-dichlorophenyl)-2-amino-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide;
[0400] (Compound No. 125)((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)phenyl)methanone; and
[0401] (Compound No. 126)(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidin-4-yl)methanone.
[0402] The pharmaceutical composition of the present invention contains the 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by the above formula 1, a pharma- ceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an active ingredient, and may be formulated into a preparation for oral administration or a preparation for parenteral administration, such as a tablet, capsule, lozenge, liquid, or suspension, by adding a conventional non-toxic pharma- ceutically acceptable carrier, reinforcing agent, or excipient thereto.
[0403] The excipients used in the pharmaceutical composition of the present invention include sweeteners, binders, solubilizers, solubilizing agents, wetting agents, emulsifiers, isotonicity agents, adsorbents, disintegrants, antioxidants, preservatives, lubricants, fillers, flavorings, etc. Examples include lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, silica, talc, stearic acid, sterin, magnesium stearate, magnesium aluminum silicate, starch, gelatin, tragacanth gum, alginic acid, sodium alginate, methylcellulose, sodium carboxymethylcellulose, agar, water, ethanol, polyethylene glycol, polyvinylpyrrolidone, sodium chloride, calcium chloride, orange essence, strawberry essence, vanilla flavor, etc.
[0404] In addition, the dosage of the compound according to the present invention to the human body may vary depending on the age, weight, sex, dosage form, health condition and degree of disease of the patient. For an adult patient weighing 70 kg, the dosage is generally 0.01 to 1,000 mg / day, and may be administered once or several times a day at regular intervals according to the judgment of a doctor or pharmacist.
[0405] Yet another aspect of the present invention is a method for producing any one of the above compounds, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, comprising the steps of:
[0406] N-(3-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0407] N-(3-(2-((4-(piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0408] N-(3-(2-((6-(piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0409] N-(3-(2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0410] N-(3-(2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide;
[0411] 4-((7-(4-(4-amino-1H-pyrazol-1-yl)piperidin-1-yl)heptyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0412] 4-((5-(4-(4-aminophenyl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
[0413] 3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoic acid;
[0414] 4-(4-(4-(3-aminopropoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol;
[0415] 2-Amino-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)acetamide;
[0416] 4-(5-hydroxy-4-(4-(piperazin-1-ylmethyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol;
[0417] 4-(5-hydroxy-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol;
[0418] (2,4-dihydroxy-5-isopropylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone;
[0419] (2,4-dihydroxy-5-isopropylphenyl)(5-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)isoindolin-2-yl)methanone;
[0420] 2-Amino-4-(2,4-dichloro-5-(2-(piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide;
[0421] 4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazola[3,4-b]pyridin-1-yl)-2-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)benzamide;
[0422] 4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-5-(3-(4-(piperidin-4-ylmethyl)piperazin-1-yl)prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine;
[0423] 4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid; and
[0424] 1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carboxylic acid;
[0425] The present invention provides a method for producing a compound, comprising the step of reacting an intermediate compound of any one of 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds selected from the group consisting of:
[0426] Meanwhile, the present invention is characterized by a method for preparing the 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds represented by the above formulas 2 and 3, and a representative method thereof is as follows.
[0427] The compound having the above chemical formula is characterized in that it has a pyrrolo[2,1-f][1,2,4]triazine skeleton.
[0428] In chemical formula 2, a cyclic hydrocarbon such as a benzene ring was introduced at position 7 from the skeleton through Suzuki reaction. Then, a cyclic compound having an amine functional group was substituted at position 2 through Buchwald reaction. Linker+E3l ligase binder was introduced from the amine functional group introduced at position 2 to synthesize the product.
[0429] In Chemical Formula 3, a cyclic hydrocarbon such as a benzene ring was introduced at position 7 from the backbone through Suzuki reaction. Then, an alkyl group having a functional group capable of cyclization was linked. Next, an alkyl group having a functional group capable of cyclization was linked at position 2, and a cyclic compound having an amine functional group was substituted through Buchwald reaction. After introducing substituents at positions 2 and 7, a cyclic compound was synthesized through a reaction capable of cyclization.
[0430] The present invention as described above will be described in more detail based on the following examples, formulation examples, and experimental examples. The following examples, formulation examples, and experimental examples are illustrative of the present invention, and the scope of the present invention is not limited thereto. EXAMPLES
[0431] Example 1: (2 1 Z,4 4 E)-41 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0432] [ka]
[0433] Step 1) Preparation of 4-(2-chloropyrrole[2,1-f][1,2,4]triazin-7-yl)phenol
[0434] 7-Bromo-2-chloropyrrole[2,1-f][1,2,4]triazine (1.0 g, 4.3 mmol) and (4-hydroxyphenyl)boronic acid (623 mg, 4.5 mmol) were dissolved in 1,4-dioxane / distilled water (16 / 4 mL) and sodium carbonate (1.37 g, 12.9 mmol) and t-ButylXphos (0.2 g, 0.47 mmol) were added. After flushing the mixture with nitrogen for 10 minutes, Pd(PPh3)Cl2 (1.45 g, 2.07 mmol) was added and stirred at 60°C for 6 hours. Upon completion of the reaction, the mixture was filtered through Celite, diluted with ethyl acetate and washed with saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The resulting residue was purified by chromatography to give the title compound 0.95 g (yield: 90%). MSM / z:246[M+1].
[0435] Step 2) Preparation of 7-(4-(2-bromoethoxy)phenyl)-2-chloropyrrole[2,1-f][1,2,4]triazine
[0436] 4-(2-chloropyrrole[2,1-f][1,2,4]triazin-7-yl)phenol (4.1 g, 16.69 mmol) was diluted in toluene (50 mL), and triphenylphosphine (6.57 g, 25.0 mmol) and 2-bromoethanol (2.4 mL, 7.64 mmol) were added. After stirring for 5 minutes, diisopropyl azocarboxylate (1.13 mL, 5.73 mmol) was slowly added thereto, and the mixture was stirred at 50° C. After the reaction was completed, the mixture was diluted with ethyl acetate, and washed with distilled water and saturated salt water. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to obtain 5 g of the title compound (yield: 85%). MSM / z: 353 [M+1].
[0437] Step 3) Preparation of tert-butyl (3-(4-((7-(4-(2-bromoethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)propyl)carbamate
[0438] 7-(4-(2-bromoethoxy)phenyl)-2-chloropyrrole[2,1-f][1,2,4]triazine (1 g, 2.83 mmol) was diluted in 20 mL of sec-butanol, and potassium carbonate (1.2 g, 8.5 mmol) and tert-butyl(3-(4-amino-1H-pyrrol-1-yl)propyl)carbamate (0.75 g, 3.11 mmol) were added. After flushing the mixture with nitrogen for 10 min, Pd2(dba)3 (0.51 g, 0.57 mmol) and Xphos (0.31 g, 0.62 mmol) were added and stirred at 80° C. for 4 h. Upon completion of the reaction, the mixture was filtered through Celite, diluted with ethyl acetate, and washed with saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The resulting residue was purified by chromatography to give 0.8 g (yield: 57%) of the title compound. MSM / z: 557 [M+1].
[0439] Step 4) Preparation of N-(1-(3-aminopropyl)-1H-pyrazol-4-yl)-7-(4-(2-bromoethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine
[0440] tert-Butyl (3-(4-((7-(4-(2-bromoethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)propyl)carbamate (2.1 g, 3.77 mmol) was diluted with DCM (50 mL) and 4M hydrochloric acid-dioxane solution (5 mL) was added. The mixture was stirred at 40° C. for 4 hours. Upon completion of the reaction, the mixture was diluted with dichloromethane and neutralized to pH 5 with sodium bicarbonate. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure and distilled under reduced pressure. The resulting title compound (1.53 g, yield: 88%) was used in the next reaction without further purification. MSM / z: 457 [M+1].
[0441] Stage 5)(2 1 Z,4 4 E)-4 1 Preparation of H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine
[0442] N-(1-(3-aminopropyl)-1H-pyrazol-4-yl)-7-(4-(2-bromoethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazine-2-amine (0.42 g, 0.92 mmol) was diluted in 2-ethoxymethanol (40 mL), diisopropylethylamine (1.0 mL) was added, and the mixture was stirred at 80° C. for two days. After the reaction was completed, the product was purified by chromatography to obtain 100 mg (29% yield) of the title compound. 1H NMR (400MHz, DMSO-d6) δ9.41(s, 1H), 8.89(s, 1H), 7.97(s, 1H), 7.78-7.73(m, 2H), 7.35-7.30 (m, 2H), 7.26(s, 1H), 6.92-6.86(m, 2H), 4.44(m, 2H), 4.11(m, 2H), 2.82(m, 4H), 1.73(m, 2H). MSM / z:376[M+1].
[0443] Example 2: 1 Z,4 4 E)-8-Methyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0444] [ka]
[0445] (2 1 Z,4 4 E)-4 1H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffeine (0.42 g, 0.92 mmol) (40 mg, 0.11 mmol) was diluted in dichloromethane (2.1 mL), and then acetic acid (1 drop) and formaldehyde (0.01 mL, 0.26 mmol) were added. After stirring for 30 minutes, sodium triacetoxyborohydride (29 mg, 0.14 mmol) was slowly added and stirred for one day. Upon completion of the reaction, the mixture was washed with dichloromethane and saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to obtain 16 mg of the title compound (yield: 38%). 1H NMR (400MHz, DMSO-d6) δ9.41(s, 1H), 8.89(s, 1H), 7.97(s, 1H), 7.78-7.73(m, 2H), 7.35-7.30(m, 2H) ), 7.26(s, 1H), 6.92-6.86(m, 2H), 4.44(m, 2H), 4.11(m, 2H), 2.82(m, 4H), 2.21(s, 3H), 1.73(m, 2H). MSM / z:390[M+1].
[0446] Example 3: 1-(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethan-1-one
[0447] [ka]
[0448] (2 1 Z,4 4 E)-4 1H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine (40 mg, 0.11 mmol) was diluted in dichloromethane (2.6 mL), and then acetyl chloride (0.015 mL, 0.22 mmol) and triethylamine (0.2 mL, 0.52 mmol) were added at 0°C, followed by stirring at room temperature for 30 minutes. Upon completion of the reaction, the mixture was diluted with ethyl acetate and washed with saturated salt water. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to obtain 14 mg of the title compound (yield: 31%). MSM / z: 418 [M+1].
[0449] Example 4: 1-(2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffein-8-yl)butan-1-one
[0450] [ka]
[0451] The title compound was obtained by the same procedure as in Example 3 using the corresponding acyl chloride. MSM / z: 446 [M+1].
[0452] Example 5: (2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)(4-chlorophenyl)methanone
[0453] [ka]
[0454] The title compound was obtained by the same procedure as in Example 3 using the corresponding acyl chloride. MSM / z: 514 [M+1].
[0455] Example 6: (2 1 Z,4 4 E)-N-Cyclohexyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine-8-carboxamide
[0456] [ka]
[0457] (2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine (40 mg, 0.11 mmol) was diluted in tetrahydrofuran (2.6 mL) and isocyanate (32 mg, 0.22 mmol) was added, followed by stirring at room temperature for 30 minutes. Upon completion of the reaction, the mixture was diluted with ethyl acetate and washed with saturated salt water. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to give the title compound 18 mg (yield: 32%). MSM / z: 501 [M+1].
[0458] Example 7: (2 1 Z,4 4 E) -N-(3-methoxyphenyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine-8-carboxamide
[0459] [ka]
[0460] Using the corresponding isocyanate, the same procedure as in Example 6 was carried out to give the title compound. MSM / z: 524 [M+1].
[0461] Example 8: (2 1 Z,4 4 E) -N-Ethyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine-8-carboxamide
[0462] [ka]
[0463] Using the corresponding isocyanate, the same procedure as in Example 6 was carried out to give the title compound. MSM / z: 477 [M+1].
[0464] Example 9: (2 1 Z,4 4 E)-8-(Methylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0465] [ka]
[0466] (2 1 Z,4 4 E)-4 1H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffeine (40 mg, 0.11 mmol) was diluted in dichloromethane (2.6 mL), and methanesulfonyl chloride (0.016 mL, 0.39 mmol) was added. Upon completion of the reaction, the mixture was washed with dichloromethane and saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to give the title compound 16 mg (yield: 33%). MSM / z: 454 [M+1].
[0467] Example 10: (2 1 Z,4 4 E)-8-((3,4-difluorophenyl)sulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0468] [ka]
[0469] The title compound was obtained by the same procedure as in Example 9 above using the corresponding sulfonyl chloride. MSM / z: 552 [M+1].
[0470] Example 11: (2 1 Z,4 4 E)-8-(phenylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0471] [ka]
[0472] The title compound was obtained by the same procedure as in Example 9 above using the corresponding sulfonyl chloride. MSM / z: 516 [M+1].
[0473] Example 12: (2 1 Z,4 4 E)-8-(Cyclopropylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0474] [ka]
[0475] The title compound was obtained by the same procedure as in Example 9 above using the corresponding sulfonyl chloride. MSM / z: 480 [M+1].
[0476] Example 13: (2 1 Z,4 4 E)-8-(propylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0477] [ka]
[0478] The title compound was obtained by the same procedure as in Example 9 above using the corresponding sulfonyl chloride. MSM / z: 482 [M+1].
[0479] Example 14: (2 1 Z,4 4 E)-8-((5-chlorothiophene-2-yl)sulfonyl)-4 1H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0480] [ka]
[0481] The title compound was obtained by the same procedure as in Example 9 above using the corresponding sulfonyl chloride. MSM / z: 556 [M+1].
[0482] Example 15: (2 1 Z,4 4 E)-8-(Cyclohexylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeine
[0483] [ka]
[0484] Using the corresponding sulfonyl chloride, the same procedure as in Example 9 was carried out to give the title compound. MSM / z: 522 [M+1].
[0485] Example 16: (Z)-5-Oxa-3,9,15-triazine-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one
[0486] [ka]
[0487] Step 1) Preparation of 2-chloro-7-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazine
[0488] The title compound was obtained by the same procedure as in Step 1 of Example 1 using the corresponding boronic acid. MSM / z: 275 [M+1].
[0489] Step 2) Preparation of 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)aniline
[0490] 2-Chloro-7-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazine (1.2 g, 4.4 mmol) was diluted in EtOH (10 mL), tin dichloride dihydrate (2.82 g, 11.0 mmol) was added, and the mixture was stirred at 80° C. for 3 hours. When the reaction was completed, the mixture was diluted with dichloromethane and neutralized to pH 5 with sodium bicarbonate. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting title compound (700 mg, yield: 65%) was used in the next reaction without further purification. MSM / z: 245 [M+1].
[0491] Step 3) Preparation of ethyl 5-((4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoate
[0492] 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)aniline (630 mg, 2.58 mmol) was dissolved in acetonitrile (8.6 mL), potassium carbonate (1.07 g, 7.74 mmol) and ethyl pentanoate (0.61 mL, 3.84 mmol) were added, and the mixture was stirred at 80° C. for 3 hours. Upon completion of the reaction, the mixture was washed with dichloromethane and saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to give the title compound 800 mg (yield: 85%). MSM / z: 373 [M+1].
[0493] Step 4) Preparation of ethyl 5-((4-(2-((4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoic acid
[0494] Ethyl 5-((4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoate (90 mg, 0.23 mmol) was diluted in 2.4 mL of sec-butanol, and potassium carbonate (0.60 g, 0.60 mmol) and tert-butyl(3-(4-aminophenoxy)propyl)carbamate (97 mg, 0.36 mmol) were added. After flushing the mixture with nitrogen for 10 min, Pd2(dba)3 (44 mg, 0.05 mmol) and Xphos (48 mg, 0.10 mmol) were added and stirred at 80 °C for 4 h. Upon completion of the reaction, the mixture was filtered through Celite, diluted with ethyl acetate, and washed with saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The resulting residue was purified by chromatography to give the title compound 60 mg (yield: 42%). MSM / z:603[M+1].
[0495] Step 5) Preparation of 5-((4-(2-((4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoic acid
[0496] Ethyl 5-((4-(2-((4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoate (90 mg) was diluted in methanol / water (4:1, v / v), lithium hydroxide was added at 0°C, and the mixture was stirred at room temperature. When the reaction was completed, the mixture was diluted with dichloromethane, adjusted to pH 3-4 with 1N HCl aqueous solution, and extracted with dichloromethane. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting title compound was used in the next reaction without further purification. MSM / z: 575 [M+1].
[0497] Step 6) Preparation of 5-((4-(2-((4-(3-aminopropoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoic acid
[0498] 5-((4-(2-((4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoic acid was added in 4M hydrochloric acid-dioxane solution. The mixture was stirred at 40° C. for 4 hours. Upon completion of the reaction, the mixture was diluted with dichloromethane and neutralized to pH 5 with sodium bicarbonate. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure and distilled under reduced pressure. The resulting title compound was used in the next reaction without further purification. MSM / z: 475[M+1].
[0499] Step 7) Preparation of (Z)-5-oxa-3,9,15-triazine-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one
[0500] 5-((4-(2-((4-(3-aminopropoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)amino)pentanoic acid was diluted in dimethylformamide, and diisopropylethylamine and HATU were added at 0°C, followed by stirring at room temperature for 1 hour. Upon completion of the reaction, the mixture was diluted with dichloromethane and washed with saturated salt water. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting title compound was used in the next reaction without further purification. MSM / z: 457[M+1].
[0501] Example 17: (1 4 Z,2 1 Z)-1 1 H-5-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1(4,1)-pyrazolan-4(1,4)-benzenecyclohexadecapan-10-one
[0502] [ka]
[0503] Step 1) Preparation of tert-butyl 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazole e-1-carboxylate
[0504] The title compound was obtained by the same procedure as in Step 1 of Example 1 above using the corresponding boronic acid. MSM / z: 320 [M+1].
[0505] Step 2) Preparation of 2-chloro-7-(1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazine
[0506] tert-Butyl 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazole e-1-carboxylate (500 mg, 2.38 mmol) was diluted in dichloromethane (2.3 mL) and trifluoroacetic acid (2.3 mL) was added at 0° C., and the mixture was stirred at room temperature for 12 hours. When the reaction was completed, the mixture was diluted with dichloromethane and neutralized with sodium bicarbonate to pH 5. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting title compound was used in the next reaction without further purification. MSM / z: 220 [M+1].
[0507] Step 3) Preparation of methyl 6-(4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazol-1-yl)heptanoate
[0508] 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)aniline (280 mg, 1.28 mmol) was dissolved in acetonitrile (2.6 mL), potassium carbonate (442 mg, 3.2 mmol) and methyl hexanoate (0.35 mL, 1.92 mmol) were added, and the mixture was stirred at 80° C. for 3 hours. Upon completion of the reaction, the mixture was washed with dichloromethane and saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to give the title compound 200 mg (yield: 45%). MSM / z: 348 [M+1].
[0509] Step 4) Preparation of methyl 6-(4-(2-((4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazol-1-yl)heptanoic acid
[0510] The title compound was obtained by the same procedure as in Step 4 of Example 16 using the corresponding aniline. MSM / z: 578 [M+1].
[0511] Stage 5)(1 4Z,2 1 Z)-1 1 Preparation of H-5-oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1(4,1)-pyrazo-4(1,4)-benzenecyclohexadecapan-10-one
[0512] Using the compound prepared in Step 4, the same procedure as in Step 5 of Example 16, Step 7 was carried out to obtain the title compound. MSM / z: 460 [M+1].
[0513] Example 18: (1 4 Z,2 1 Z,4 4 E)-1 1 H, 4 1 H-3,8-Diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(4,1)-dipyrazolacylpentadecapan-9-one
[0514] [ka]
[0515] The title compound was obtained by carrying out the same procedure as in Example 17. MSM / z: 434 [M+1].
[0516] Example 19: (1 4 Z,2 1 Z)-1 1 H-3-Aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1(4,1)-pyrazolan-4(1,4)-benzenecyclododecapane-9-one
[0517] [ka]
[0518] The title compound was obtained by carrying out the same procedure as in Example 17. MSM / z: 471 [M+1].
[0519] Example 20: (Z)-13-Fluoro-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one
[0520] [ka]
[0521] Step 1) Preparation of 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluorophenol
[0522] Using the corresponding boronic acid, the same procedure as in Step 1 of Example 1 was carried out to obtain the title compound. MSM / z: 264 [M+1].
[0523] Step 2) Preparation of methyl 7-(4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluorophenoxy)heptanoate
[0524] 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluorophenol (400 mg, 1.52 mmol) was dissolved in acetonitrile (5.5 mL), potassium carbonate (570 mg, 3.8 mmol) and methylheptanoic acid (0.34 mL, 1.82 mmol) were added, and the mixture was stirred at 80° C. for 3 hours. Upon completion of the reaction, the mixture was washed with dichloromethane and saturated brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to give the title compound 514 mg (yield: 83%). MSM / z: 406 [M+1].
[0525] Step 3) Preparation of methyl 7-(4-(2-((4-(3-((tert-butoxycarbonyl)amino)propoxy)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-fluorophenoxy)heptanoate
[0526] The title compound was obtained by the same procedure as in Step 4 of Example 16 using the corresponding aniline. MSM / z: 636 [M+1].
[0527] Step 4) Preparation of (Z)-13-fluoro-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one
[0528] Using the compound prepared in Step 3, the same procedure as in Step 5 of Example 16, Step 7 was carried out to obtain the title compound. MSM / z: 504 [M+1].
[0529] Example 21: (2 1 Z,4 4 E)-13-Fluoro-4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolan-1(1,4)-benzenecyclohexadecapan-9-one
[0530] [ka]
[0531] The title compound was obtained by carrying out the same procedure as in Example 20. MSM / z: 478 [M+1].
[0532] Example 22: (Z)-1 3 -Fluoro-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one
[0533] [ka]
[0534] The title compound was obtained by carrying out the same procedure as in Example 20. MSM / z: 504 [M+1].
[0535] Example 23: (Z)-17-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one
[0536] [ka]
[0537] Step 1) Preparation of 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenol
[0538] The title compound was obtained by the same procedure as in Step 1 of Example 1 using the corresponding boronic acid (yield: 90%). MSM / z: 246 [M+1].
[0539] Step 2) Preparation of methyl 7-(4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)heptanoate
[0540] Using 4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenol, the same procedure as in Step 2 of Example 20 was carried out to obtain the title compound. MSM / z: 388 [M+1].
[0541] Step 3) Preparation of methyl 7-(4-(2-((4-(4-(3-((tert-butoxycarbonyl)amino)propyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)heptanoic acid
[0542] The title compound was obtained by the same procedure as in Step 4 of Example 16 using the corresponding aniline. MSM / z: 686 [M+1].
[0543] Step 4) Preparation of (Z)-17-oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one
[0544] Using the compound prepared in Step 3, the same procedure as in Step 5 of Example 16, Step 7 was carried out to obtain the title compound. MSM / z: 504 [M+1].
[0545] Example 24: (Z)-13-Oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one
[0546] [ka]
[0547] Step 1) Preparation of tert-butyl 4-(4-((7-(4-((7-methoxy-7-oxoheptyl)oxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazine-1-carboxylate
[0548] The compound prepared in step 2 of Example 23 and the corresponding aniline were used in the same manner as in step 4 of Example 16 to obtain the title compound. MSM / z: 497 [M+1].
[0549] Step 2) Preparation of (Z)-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one
[0550] Using the compound prepared in Step 1, the same procedure as in Step 5 of Example 16, Step 7 was carried out to obtain the title compound. MSM / z: 629 [M+1].
[0551] Example 25: (2 1 Z,44 E)-4 1 H-11-Oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazolan-1(1,4)-benzenecycloundecapan-6-one
[0552] [ka]
[0553] Step 1) Preparation of ethyl 5-(4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)pentanoate
[0554] The title compound was obtained by using ethyl 5-bromopentanoate in Step 1 of Example 23 above. MSM / z: 373 [M+1].
[0555] Stage 2)(2 1 Z,4 4 E)-4 1 Preparation of H-11-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecapan-6-one
[0556] The title compound was obtained by carrying out the same procedure as in Step 7 of Example 16 using the compound prepared in Step 1. MSM / z: 458 [M+1].
[0557] Example 26: (2 1 Z,4 4 E)-4 1 H-15-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazolan-1(1,4)-benzenecyclopentadecapan-10-one
[0558] [ka]
[0559] The title compound was obtained by the same procedure as in Example 25 above using the corresponding aniline. MSM / z: 515 [M+1].
[0560] Example 27: (2 1 Z,4 4 E)-4 1 H-17-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazolan-1(1,4)-benzenecycloheptadecapan-10-one
[0561] [ka]
[0562] The title compound was obtained by the same procedure as in Example 25 above using the corresponding aniline. MSM / z: 675 [M+1].
[0563] Example 28: (Z)-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one
[0564] [ka]
[0565] Step 1) Preparation of ethyl 2-(2-(4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)ethoxy)acetate
[0566] Using ethyl 2-(2-bromoethoxy)acetate, the same procedure as in Step 2 of Example 23 was carried out to give the title compound. MSM / z: 376 [M+1].
[0567] Step 2) Preparation of (Z)-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one
[0568] The title compound was obtained by the same procedure as in Example 24 above using the corresponding aniline. MSM / z: 460 [M+1].
[0569] Example 29: (Z)-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one
[0570] [ka]
[0571] Using the corresponding aniline, the same procedure as in Example 71 was carried out to give the title compound. MSM / z: 486 [M+1].
[0572] Example 30: (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecaffeine
[0573] [ka]
[0574] Step 1) Preparation of tert-butyl (3-(4-((7-(4-(2-bromoethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenoxy)propyl)carbamate
[0575] Using the corresponding aniline, the same procedure as in Step 3 of Example 1 was carried out to obtain the title compound. MSM / z: 582 [M+1].
[0576] Step 2) Preparation of (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecaffeine
[0577] The compound prepared in step 1 was diluted in dichloromethane (5 mL) and 4M hydrochloric acid-dioxane solution was added. The mixture was stirred at 40° C. for 4 hours. When the reaction was completed, the mixture was diluted with dichloromethane, neutralized with sodium bicarbonate to pH 5, and extracted with isopropylamine / chloroform (1:4, v / v) solution. The organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting title compound was used in the next reaction without further purification (yield: 88%). MSM / z: 483 [M+1]. The resulting bromoamine was diluted in dimethylformamide (4 mL), and diisopropylethylamine (5 equivalents) was added and stirred at 80° C. for 12 hours. When the reaction was completed, it was diluted with ethyl acetate and washed with saturated brine. The resulting organic layer was dried over anhydrous sodium sulfate and purified by chromatography to obtain the title compound (yield: 29%). MSM / z: 402 [M+1].
[0578] Example 31: (Z)-1-(5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl)propan-1-one
[0579] [ka]
[0580] The compound prepared in step 2 of Example 30 was diluted in tetrahydrofuran (1 ml) and triethylamine (3 equivalents) was added at 0° C. Then, acetyl chloride (1.2 equivalents) was added and stirred at 0° C. for 20 minutes. After the reaction was completed, it was diluted with ethyl acetate and washed with saturated brine. The resulting organic layer was dried over anhydrous sodium sulfate and purified by chromatography to obtain the title compound (yield: 57%). MSM / z: 582 [M+1].
[0581] Example 32: (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl(4-chlorophenyl)methanone
[0582] [ka]
[0583] The corresponding acyl chloride was used in the same manner as in Example 31 to obtain the title compound (yield: 88%). MSM / z: 540 [M+1].
[0584] Example 33: (2 1 Z,7Z)-5,10-dioxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclodecapan-7-ene
[0585] [ka]
[0586] Step 1) 4-(2-((4-hydroxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenol
[0587] Using the aniline corresponding to the compound prepared in step 1 of Example 1, the same procedure as in step 4 of Example 1 was carried out to obtain the title compound (yield: 62%). MSM / z: 319 [M+1].
[0588] Step 2) Preparation of N,7-bis(4-(allyloxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine
[0589] 4-(2-((4-hydroxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenol was dissolved in dimethylformamide (5 mL), potassium carbonate (5 eq.) and allyl bromide (3 eq.) were added, and the mixture was stirred at 50° C. for 2 hours. Upon completion of the reaction, the mixture was diluted with ethyl acetate and washed with saturated brine. The resulting organic layer was dried over anhydrous sodium sulfate and purified by chromatography to give the title compound (yield: 78%). MSM / z: 399 [M+1].
[0590] Stage 3)(2 1 Preparation of Z,7Z)-5,10-dioxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclodecapan-7-ene
[0591] N,7-bis(4-(allyloxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine was diluted in toluene (10 mL), Grubbs II catalyst (10 Mol%) was added, and the mixture was stirred at 100° C. for 40 hours. After completion of the reaction, the product was distilled under reduced pressure and purified by chromatography to obtain the title compound (yield: 12%). MSM / z: 371 [M+1].
[0592] Example 34: (Z)-4 2 -Methoxy-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one
[0593] [ka]
[0594] The title compound was obtained by the same procedure as in Example 24 above using the corresponding aniline. MSM / z: 490 [M+1].
[0595] Example 35: (2 1 Z,4 4 E)-4 1H-11,14-dioxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclotetradecapan-9-one
[0596] [ka]
[0597] Step 1) Preparation of ethyl 2-(2-(4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)ethoxy)acetate
[0598] Using tert-butyl (3-(4-aminophenoxy)propyl)carbamate, the same procedure as in step 2 of Example 1 was carried out to obtain the title compound (yield: 58%). MSM / z: 376 [M+1].
[0599] Stage 2)(2 1 Z,4 4 E)-4 1 Preparation of H-11,14-dioxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclotetradecapan-9-one
[0600] Using the corresponding aniline, the same procedure as in step 4 of example 1, step 7 was carried out to obtain the title compound. MSM / z: 434 [M+1].
[0601] Example 36: (2 1 Z,4 4 E)-4 1 H-14-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolan-1(1,4)-benzenecyclotetradecapan-9-one
[0602] [ka]
[0603] The title compound was obtained by the same procedure as in Example 25 above using the corresponding aniline. MSM / z: 432 [M+1].
[0604] Example 37: (2 1 Z,4 4 E)-4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolan-1(1,4)-benzenecyclohexadecapan-9-one
[0605] [ka]
[0606] The title compound was obtained by the same procedure as in Example 24 above using the corresponding aniline. MSM / z: 460 [M+1].
[0607] Example 38: (Z)-5,15-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one
[0608] [ka]
[0609] The title compound was obtained by the same procedure as in Example 25 above using the corresponding aniline. MSM / z: 458 [M+1].
[0610] Example 39: N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0611] [ka]
[0612] Step 1: N-(3-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0613] 7-Bromo-2-chloropyrrole[2,1-f][1,2,4]triazine (1.0g, 4.31mmol) and (3-(methanesulfonamido)phenyl)boronic acid (972mg, 4.53mmol) were dissolved in 1,4-dioxane (28mL) and 2.0N sodium carbonate (13mL), and then t-ButylXphos (182mg, 0.43mmol) was added. After purging the mixture with nitrogen for 10 minutes, Pd(PPh3)Cl2 (302mg, 0.43mmol) was added and the mixture was stirred at 60℃ for 6 hours. When the reaction was complete, the mixture was filtered through Celite, and the filtrate was diluted with ethyl acetate and then wiped with salt water. The organic layer was dried over magnesium sulfate and concentrated. The target compound (1.1g, 86% yield) was obtained by chromatographic purification. MSM / z: 323[M+1].
[0614] Step 2: tert-Butyl 4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazine-1-carboxylate
[0615] N-(3-(2-c-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide (1.0 g, 3.11 mmol) was dissolved in 17 mL of sec-butanol, and then calcium carbonate (1.8 g, 12.8 mmol) and tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate (861 mg, 3.11 mmol) were added. Nitrogen was purged into the mixture for 10 minutes, and then Pd2(dba)3 (570 mg, 0.62 mmol) and Xphos (300 mg, 0.62 mmol) were added. The reaction mixture was stirred at 80°C for 6 hours. When the reaction was completed, the mixture was filtered through Celite, and the filtrate was diluted with ethyl acetate and wiped with salt water. The organic layer was dried over magnesium sulfate and concentrated. The target compound (1.17 g, 67% yield) was obtained by chromatographic purification. MSM / z:564[M+1].
[0616] Step 3: N-(3-(2-((4-(piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0617] tert-Butyl 4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazine-1-carboxylate (0.1 g, 0.18 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.3 mL) was added. After completion of the reaction, it was dried under reduced pressure and used in the next reaction without purification. MSM / z: 464 [M+1].
[0618] Step 4: N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)pentyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0619] N-(3-(2-((4-(piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide (100 mg, 0.22 mmol), potassium iodide (73 mg, 0.22 mmol), diisopropylethylamine (0.12 mL, 0.66 mmol) and 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (186 mg, 0.44 mmol) were dissolved in dimethylformamide (2 mL). The reaction mixture was stirred at 60° C. for 12 hours. When the reaction was completed, the reaction mixture was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The target compound (101 mg, 57% yield) was obtained by chromatographic purification. MSM / z:806[M+1].
[0620] Example 40: N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)propyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0621] [ka]
[0622] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((5-bromopropyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0623] Example 41: N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0624] [ka]
[0625] The experimental method was the same as that of Example 39, except that in step 4 of Example 1, 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromoheptyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0626] Example 42: N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0627] [ka]
[0628] The experimental method is the same as that of Example 39, except that in step 4 of Example 1, 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0629] Example 43: N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0630] [ka]
[0631] The experimental method is the same as that of Example 1, except that in step 4 of Example 39, 4-((5-bromoethyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0632] Example 44: N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)butyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0633] [ka]
[0634] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((5-bromobutyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0635] Example 45: N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0636] [ka]
[0637] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((5-bromohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0638] Example 46: N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0639] [ka]
[0640] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((5-bromooctyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0641] Example 47: N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0642] [ka]
[0643] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0644] Example 48: -(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0645] [ka]
[0646] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-(2-bromoethoxy)ethoxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione.
[0647] Example 49: N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0648] [ka]
[0649] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((6-bromohexyl)oxy)-2-(2-oxocyclohexyl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0650] Example 50: N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0651] [ka]
[0652] The experimental method was the same as that of Example 39, except that in step 4 of Example 39, 4-((6-bromooctyl)oxy)-2-(2-oxocyclohexyl)isoindoline-1,3-dione was used instead of 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
[0653] Example 51: N-(3-(2-((4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0654] [ka]
[0655] N-(3-(2-((4-(piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide (100mg, 0.22mmol), 1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidine-4-carbaldehyde (128mg, 0.33mmol) and acetic acid (1 drop) were dissolved in dichloromethane (2mL). Sodium triacetoxyborohydride (140mg, 0.66mmol) was added and the reaction mixture was stirred at room temperature for 3 hours. When the reaction was completed, water was added to terminate the reaction, and the mixture was diluted with dichloromethane and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. Purification by chromatography gave the target compound (113 mg, 62% yield). MSM / z: 835 [M+1].
[0656] Example 52: N-(3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0657] [ka]
[0658] Step 1: 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-nitro-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione
[0659] 4-(4-nitro-1H-pyrazol-1-yl)piperidine (1.5 g, 7.61 mmol), potassium iodide (2.5 g, 15.22 mmol), diisopropylethylamine (4 mL, 22.83 mmol) and 4-((9-bromononyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (186 mg, 0.44 mmol) were dissolved in dimethylformamide (15 mL). The reaction mixture was stirred at 60° C. for 12 hours. When the reaction was complete, the reaction mixture was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The target compound was obtained by chromatographic purification. MSM / z: 595 [M+1].
[0660] Step 2: 4-((9-(4-(4-amino-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0661] 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-nitro-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione (1 g, 1.68 mmol) was dissolved in ethyl acetate (20 mL), and Pd / C (100 mg) was added. The mixture was stirred at room temperature under balloon pressure filled with hydrogen gas for one day. The reaction mixture was filtered through Celite and concentrated. The target compound was used in the next reaction without purification. MSM / z: 565 [M+1].
[0662] Step 3: N-(3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0663] The experimental method was the same as in Example 1, except that 4-((9-(4-(4-amino-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate in step 2. MSM / z: 851 [M+1].
[0664] Example 53: 3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-N-methylbenzamide
[0665] [ka]
[0666] The experimental method was the same as in Example 39, except that (3-(methylcarbamoyl)phenyl)boronic acid was used instead of (3-(methanesulfonamido)phenyl)boronic acid in Step 1.
[0667] Example 54: 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-phenylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione
[0668] [ka]
[0669] The experimental method was the same as in Example 39, except that in step 1, phenylboronic acid was used instead of (3-(methanesulfonamido)phenyl)boronic acid.
[0670] Example 55: 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione
[0671] [ka]
[0672] The experimental method was the same as in Example 39, except that (1-methyl-1H-pyrazol-4-yl)boronic acid was used instead of (3-(methanesulfonamido)phenyl)boronic acid in Step 1.
[0673] Example 56: 4-((9-(4-(4-((7-(1H-indol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0674] [ka]
[0675] The experimental method was the same as in Example 39, except that (1H-indol-6-yl)boronic acid was used instead of (3-(methanesulfonamido)phenyl)boronic acid in Step 1.
[0676] Example 57: 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(4-hydroxyphenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione
[0677] [ka]
[0678] The experimental method was the same as in Example 39, except that in step 1, (4-hydroxyphenyl)boronic acid was used instead of (3-(methanesulfonamido)phenyl)boronic acid.
[0679] Example 58: Methyl-7-(4-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)heptanoic acid
[0680] [ka]
[0681] The experimental method was the same as in Example 52, except that in step 3, methyl-7-(4-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)heptanoic acid was used instead of N-(3-(2-chloropyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide.
[0682] Example 59: N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0683] [ka]
[0684] The experimental method was the same as in Example 39, except that in step 2, tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0685] Example 60: N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0686] [ka]
[0687] The experimental method was the same as in Example 40, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0688] Example 61: N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0689] [ka]
[0690] The experimental method was the same as in Example 41, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0691] Example 62: N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0692] [ka]
[0693] The experimental method was the same as in Example 42, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0694] Example 63: N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0695] [ka]
[0696] The experimental method was the same as in Example 43, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0697] Example 64: N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0698] [ka]
[0699] The experimental method was the same as in Example 44, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0700] Example 65: N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0701] [ka]
[0702] The experimental method was the same as in Example 45, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0703] Example 66: N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0704] [ka]
[0705] The experimental method was the same as in Example 46, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0706] Example 67: N-(3-(2-((4-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0707] [ka]
[0708] The experimental method was the same as in Example 47, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0709] Example 68: N-(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0710] [ka]
[0711] The experimental method was the same as in Example 48, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0712] Example 69: N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0713] [ka]
[0714] The experimental method was the same as in Example 49, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0715] Example 70: N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0716] [ka]
[0717] The experimental method was the same as in Example 50, except that tert-butyl-4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0718] Example 71: N-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0719] [ka]
[0720] The experimental method was the same, except that in Example 51, tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate.
[0721] Example 72: N-(3-(2-((6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0722] [ka]
[0723] The experimental method was the same as in Example 40, except that tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0724] Example 73: N-(3-(2-((6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0725] [ka]
[0726] The experimental method was the same, except that in Example 42, tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate.
[0727] Example 74: N-(3-(2-((6-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0728] [ka]
[0729] The experimental method was the same as in Example 43, except that tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0730] Example 75: N-(3-(2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0731] [ka]
[0732] The experimental method was the same as in Example 44, except that tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0733] Example 76: N-(3-(2-((6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0734] [ka]
[0735] The experimental method was the same, except that in Example 45, tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate.
[0736] Example 77: N-(3-(2-((6-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0737] [ka]
[0738] The experimental method was the same as in Example 46, except that tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0739] Example 78: N-(3-(2-((6-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0740] [ka]
[0741] The experimental method was the same as in Example 47, except that tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0742] Example 79: N-(3-(2-((6-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0743] [ka]
[0744] The experimental method was the same, except that in Example 48, tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate.
[0745] Example 80: N-(3-(2-((6-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0746] [ka]
[0747] The experimental method was the same as in Example 49, except that tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0748] Example 81: N-(3-(2-((6-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0749] [ka]
[0750] The experimental method was the same as in Example 50, except that tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate.
[0751] Example 82: N-(3-(2-((6-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0752] [ka]
[0753] The experimental method was the same, except that in Example 51, tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate.
[0754] Example 83: (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetamino)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
[0755] [ka]
[0756] Step 1: Ethyl-2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetate
[0757] N-(3-(2-((4-(piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide (100 mg, 0.22 mmol), potassium iodide (73 mg, 0.22 mmol), diisopropylethylamine (0.12 mL, 0.66 mmol) and ethyl-2-(2-chloroethoxy)acetate (73 mg, 0.44 mmol) were dissolved in dimethylformamide (2 mL). The reaction mixture was stirred at 60° C. for 24 hours. Upon completion of the reaction, the reaction mixture was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The target compound (99 mg, 76% yield) was obtained by chromatographic purification. MSM / z: 594 [M+1].
[0758] Step 2: 2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetic acid
[0759] Ethyl-2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetate (99 mg, 0.17 mmol) was dissolved in tetrahydrofuran (1 mL), methanol (1 mL), and water (1 mL), and LiOH-H2O (15 mg, 0.34 mmol) was added. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with ethyl acetate, neutralized with 1N aqueous hydrogen chloride solution to pH 5, and then washed with brine. The organic layer was dried over magnesium sulfate and concentrated to give the target compound (92 mg, 94% yield). It was used in the next reaction without purification. MSM / z: 566 [M+1].
[0760] Step 3: (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetamino)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
[0761] 2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetic acid (92 mg, 0.16 mmol), PyBOP (166 mg, 0.32 mmol) and (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (103 mg, 0.24 mmol) were dissolved in dimethylformamide (2 mL), and diisopropylethylamine (0.1 mL, 0.48 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. When the reaction was completed, the reaction mixture was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. It was purified by chromatography to give the target compound (88 mg, 56% yield). MSM / z: 978 [M+1].
[0762] Example 84: (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
[0763] [ka]
[0764] Step 1: tert-Butyl-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoic acid
[0765] The experimental method was the same as in Example 45, except that in step 1, tert-butyl-3-(2-(2-iodoethoxy)ethoxy)propanoate was used instead of ethyl-2-(2-chloroethoxy)acetate.
[0766] Step 2: 3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoic acid
[0767] The experimental method was the same as in Example 1, except that in step 3, tert-butyl-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazine-1-carboxylate was used instead of tert-butyl 4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoic acid.
[0768] Step 3: (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
[0769] The experimental method was the same as in Example 45, except that in step 3, 3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)propanoic acid was used instead of 2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy ....
[0770] Example 85: (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide
[0771] [ka]
[0772] The experimental method was the same as in Example 84, except that in step 3, (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide was used instead of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide.
[0773] Example 86: 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0774] [ka]
[0775] Step 1) 2-Bromo-7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazine
[0776] The experimental procedure was the same as in Example 39, except that (4-(trifluoromethoxy)phenyl)boronic acid was used instead of (3-(methanesulfonamido)phenyl)boronic acid (972 mg, 4.53 mmol) in step 1. MSM / z: 359 [M+1].
[0777] Step 2) Preparation of 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-nitropyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0778] 1-(5-Nitropyridin-2-yl)piperazine (1 eq.), 4-((5-bromopentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.2 eq.), potassium iodide (1 eq.), and diisopropylethylamine (2.5 eq.) were dissolved in dimethylformamide. The reaction mixture was stirred at 65° C. for 2 hours. Upon completion of the reaction, it was diluted with ethyl acetate and washed with brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and evaporated under reduced pressure. The resulting residue was purified by chromatography to give the title compound. MSM / z: 550 [M+1].
[0779] Step 3) Preparation of 4-((5-(4-(4-aminophenyl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0780] 2-(2,6-Dioxopiperidin-3-yl)-4-((5-(4-(5-nitropyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione (1 eq), ammonium chloride (10 eq), and iron powder (10 eq) were dissolved in tetrahydrofuran / methanol / water (4:2:1). The reaction mixture was stirred at 80° C. for 1 h. Upon completion of the reaction, the mixture was diluted with ethyl acetate, washed with aqueous sodium bicarbonate, and then with brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. MSM / z: 520 [M+1].
[0781] Step 4) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0782] 2-Chloro-7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazine (1 equivalent) was dissolved in sec-butanol / toluene (1:1), and then calcium carbonate (4 equivalents) and 4-((5-(4-(4-aminophenyl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1 equivalent) were added. Nitrogen was purged into the mixture for 10 minutes, and then Pd2(dba)3 (0.1 equivalent) and Xphos (0.1 equivalent) were added. The reaction mixture was stirred at 85°C for 6 hours. When the reaction was complete, the mixture was filtered through Celite, and the filtrate was diluted with ethyl acetate and wiped with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound was obtained by chromatographic purification. MSM / z:798[M+1].
[0783] Example 87: 4-((5-(4-(5-((7-(3,5-difluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0784] [ka]
[0785] The experimental method was the same as in Example 86, except that (3,5-difluorophenyl)boronic acid was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 750 [M+1].
[0786] Example 88: 4-((5-(4-(5-((7-(2-aminopyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0787] [ka]
[0788] The experimental procedure was the same as in Example 86, except that (2-aminopyrimidin-5-yl)boronic acid was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 731 [M+1].
[0789] Example 89: 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(quinolin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0790] [ka]
[0791] The experimental procedure was the same as in Example 86, except that quinolin-3-ylboronic acid was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 765 [M+1].
[0792] Example 90: tert-Butyl 4-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)benzyl)piperazine-1-carboxylate
[0793] [ka]
[0794] The experimental procedure was the same as in Example 86, except that tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine-1-carboxylate was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 913 [M+1].
[0795] Example 91: (E)-2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-styrylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0796] [ka]
[0797] The experimental procedure was the same as in Example 86, except that tert-butyl (E)-styrylboronic acid was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 740 [M+1].
[0798] Example 92: tert-Butyl 4-(4-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate
[0799] [ka]
[0800] The experimental method was the same as in Example 86, except that in step 1, tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate was used instead of (4-(trifluoromethoxy)phenyl)boronic acid. MSM / z: 888 [M+1].
[0801] Example 93: 4-((5-(4-(5-((7-(4-(dimethylamino)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0802] [ka]
[0803] The experimental method was the same as in Example 86, except that N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 757 [M+1].
[0804] Example 94: 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(pyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0805] [ka]
[0806] The experimental procedure was the same as in Example 86, except that pyridin-4-ylboronic acid was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 715 [M+1].
[0807] Example 95: 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(thiazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0808] [ka]
[0809] The experimental procedure was the same as in Example 86, except that 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 721 [M+1].
[0810] Example 96: 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0811] [ka]
[0812] The experimental method was the same as in Example 86, except that 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole was used instead of (4-(trifluoromethoxy)phenyl)boronic acid in step 1. MSM / z: 788 [M+1].
[0813] Example 97: 4-((5-(4-(5-((7-((3,5-difluorophenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0814] [ka]
[0815] Step 1) Preparation of 2-chloro-7-((3,5-difluorophenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazine
[0816] 7-Bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (1 eq), 1-ethynyl-3,5-difluorobenzene (1.5 eq), copper iodide (0.1 eq), diisopropylamine (3 eq), PdCl2(Ph3)2 (0.1 eq) were dissolved in sec-butanol / toluene (1:1). The reaction mixture was purged with nitrogen for 10 minutes and then stirred at 85°C for 6 hours. Once the reaction was complete, the mixture was filtered through Celite, and the filtrate was diluted with ethyl acetate and then wiped with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound was obtained by chromatographic purification. MSM / z: 290 [M+1].
[0817] Step 2) Preparation of 4-((5-(4-(5-((7-((3,5-difluorophenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0818] The experimental method was the same as that of step 4 of Example 86, except that 2-chloro-7-((3,5-difluorophenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazine was used instead of 2-chloro-7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazine in step 4 of Example 86. MSM / z: 774[M+1].
[0819] Example 98: 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-((3-methoxyphenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)aminopyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione
[0820] [ka]
[0821] The experimental method was the same as in Example 97, except that 1-ethynyl-3-methoxybenzene was used instead of 1-ethynyl-3,5-difluorobenzene. MSM / z: 678 [M+1].
[0822] Example 99: N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0823] [ka]
[0824] 3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoic acid (60 mg, 0.10 mmol), EDCI (56 mg, 0.29 mmol), and HOAt (40 mg, 0.29 mmol) were dissolved in dimethylformamide (2 mL), and then diisopropylethylamine (0.08 mL, 0.49 mmol) was added. The reaction mixture was stirred at room temperature for 30 minutes, and then 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione (50 mg, 0.11 mmol) was added and stirred at 50° C. for 6 hours. Upon completion of the reaction, the reaction mixture was diluted with dichloromethane and washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound was obtained by chromatographic purification. MSM / z: 1064 [M+1].
[0825] Example 100: N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide
[0826] [ka]
[0827] Step 1) Preparation of t-butyl (3-(4-nitrophenoxy)propyl)carbamate
[0828] 4-Nitrophenol (4g, 28.75mmol) and t-butyl(3-bromopropyl)carbamate (8.22g, 34.505mmol) were dissolved in acetonitrile (9.6mL), and potassium carbonate (7.95g, 57.51mmol) was added. The reaction solution was stirred at 80°C for 20 hours. Upon completion of the reaction, the mixture was filtered through Celite, and the filtrate was diluted with ethyl acetate and then wiped with brine. The organic layer was dried over sodium sulfate and concentrated. The product was used in the next reaction without purification. MSM / z: 297[M+1].
[0829] Step 2) Preparation of t-butyl (3-(4-aminophenoxy)propyl)carbamate
[0830] t-Butyl (3-(4-nitrophenoxy)propyl)carbamate (6 g, 22.53 mmol) was dissolved in acetonitrile (45 mL), and Pd / C (10% wt, 600 mg) was added. The mixture was stirred under hydrogen pressure for 12 hours. Upon completion of the reaction, the mixture was filtered through Celite and purified by chromatography to obtain the title compound (4.01 g, 67% yield). MSM / z: 267 [M+1].
[0831] Step 3) Preparation of t-butyl (3-(4-(2,4-dihydroxy-5-isopropylphenylthioamido)phenoxy)propyl)carbamate
[0832] 2,4-Dihydroxy-5-isopropylbenzodithioic acid (3.4g, 14.9mmol) was dissolved in 12mL of N,N-dimethylformamide, and sodium bicarbonate (3.78g, 44.97mmol) and sodium chloroacetate (2.6g, 22.48mmol) were added at 0℃. t-Butyl (3-(4-aminophenoxy)propyl)carbamate (972mg, 4.53mmol) was dissolved in 12mL of N,N-dimethylformamide and added dropwise, and the mixture was stirred at 70℃ for 2 hours. When the reaction was completed, the reaction solution was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over sodium sulfate and concentrated. The title compound (5.2g, 75% yield) was obtained by chromatographic purification. 1H NMR (400MHz, DMSO-d6) δ11.41(s, 1H), 11.27(s, 1H), 10.07(s, 1H), 7.78(s, 1H), 7.59-7.51(m, 2H), 7.01-6. 90(m, 3H), 6.40(s, 1H), 3.98(t, 3.13-3.01(m, 3H), 1.83(p, 2H), 1.38(s, 9H), 1.16(d, 6H). MSM / z:461[M+1].
[0833] Step 4) Preparation of tert-butyl (3-(4-(7-hydroxy-6-isopropyl-2-oxo-4-thioxo-2H-benzo[e][1,3]oxazin-3(4H)-yl)phenoxy)propyl)carbamate
[0834] 2,4-Dihydroxy-5-isopropylbenzodithioic acid (5.1 g, 11.01 mmol) was dissolved in 22 mL of tetrahydrofuran, and carbonyldiimidazole (3.57 g, 22.02 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours. When the reaction was completed, the reaction solution was diluted with ethyl acetate and washed with salt water. The organic layer was dried over sodium sulfate and concentrated. It was used in the next reaction without purification. MSM / z: 487 [M+1].
[0835] Step 5) Preparation of t-butyl (3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)carbamate
[0836] tert-Butyl (3-(4-(7-hydroxy-6-isopropyl-2-oxo-4-thioxo-2H-benzo[e][1,3]oxazin-3(4H)-yl)phenoxy)propyl)carbamate (5.6 g, 11.50 mmol) was dissolved in absolute ethanol (57 mL), and hydrazine hydrate (1.15 g, 22.995 mmol) was added. Upon completion of the reaction, the reaction solution was diluted with ethyl acetate and washed with brine. The organic layer was dried over sodium sulfate and concentrated. The product was purified by chromatography to obtain the title compound (3.86 g, 69% yield). 1H NMR (300MHz, DMSO-d6) δ11.85(s, 1H), 9.56(s, 1H), 9.38(s, 1H), 7.14-7.03(m, 2H), 6.95-6.85(m, 3H) ), 6.80(s, 1H), 6.25(s, 1H), 3.94(t, 2H), 3.12-2.87(m, 3H), 1.80(p, 2H), 1.37(s, 9H), 0.98(d, 6H). MSM / z:485[M+1].
[0837] Step 6) Preparation of 4-(4-(4-(3-aminopropoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol
[0838] t-Butyl (3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)carbamate (2.75 g, 6.19 mmol) was dissolved in dichloromethane (30 mL). 4M HCl 1,4-dioxane (27 mL) was added at 0° C. The mixture was stirred at room temperature for 4 hours. After the reaction was completed, the mixture was dried under reduced pressure. It was used in the next reaction without purification. 1H NMR (400MHz, DMSO-d6) δ11.88(s, 1H), 9.65(s, 1H), 9.41(s, 1H), 7.95(s, 3H), 7.14-7.05(m, 2H), 6.9 8-6.87(m, 2H), 6.83(s, 1H), 6.28(s, 1H), 4.03(t, 2H), 3.06-2.86(m, 3H), 1.99(p, 2H), 0.99(d, 6H). MSM / z:385[M+1].
[0839] Step 7) N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide
[0840] The experimental method was the same as in Example 99, except that 2-amino-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)acetamide was used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 991 [M+1].
[0841] Example 101: N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide
[0842] [ka]
[0843] Step 1) tert-Butyl (2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxaethyl)carbamate
[0844] 4-(4-(4-(3-aminopropoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol (500 mg, 1.10 mmol), (t-butoxycarbonyl)glycine (175 mg, 1.51 mmol) were dissolved in dimethylformamide (3.7 mL), and diisopropylethylamine (0.76 mL, 4.39 mmol) was slowly added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. When the reaction was completed, it was diluted with dichloromethane and wiped with salt water. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to obtain 495 mg of the title compound (yield: 83%). MSM / z: 542 [M+1].
[0845] Step 2) 2-amino-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)acetamide
[0846] 2-Amino-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)acetamide (495 mg) was dissolved in 5 mL of dichloromethane, and 4M hydrochloric acid-dioxane solution (5 mL) was slowly added dropwise at 0° C. The reaction mixture was stirred at room temperature for 1 hour. When the reaction was completed, the title compound was obtained by distillation under reduced pressure. MSM / z: 442 [M+1].
[0847] Step 3) N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide
[0848] The experimental method was the same as in Example 99, except that 2-amino-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)acetamide was used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1048 [M+1].
[0849] Example 102: N-(3-(2-((4-(4-(2-(2-(3-(4-(4-(3-(2,4-dihydroxy-5-isophenylpropyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0850] [ka]
[0851] Step 1) Preparation of 4-(5-hydroxy-4-(4-(piperazin-1-ylmethyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol
[0852] The experimental procedure was the same as in Example 100, except that t-butyl 4-(4-aminobenzyl)piperazine-1-carboxylate was used instead of t-butyl (3-(4-aminophenoxy)propyl)carbamate (972 mg, 4.53 mmol) in step 3. MSM / z: 410 [M+1].
[0853] Step 2) N-(3-(2-((4-(4-(2-(2-(3-(4-(4-(3-(2,4-dihydroxy-5-isophenylpropyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0854] The experimental method is the same as in Example 99, except that 4-(5-hydroxy-4-(4-(piperazin-1-ylmethyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1016 [M+1].
[0855] Example 103: N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0856] [ka]
[0857] Step 1) Preparation of 4-(5-hydroxy-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol
[0858] 4-(5-Hydroxy-4-(4-(piperazin-1-ylmethyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol (300 mg, 0.73 mmol), tert-butyl 4-formylpiperidine-1-carboxylate (312 mg, 1.47 mmol), acetic acid (4 mg, 0.07 mmol) were diluted in dichloroethylene (5 mL), and sodium triacetoxyborohydride (309 mg, 1.47 mmol) was slowly added dropwise at 0°C. The reaction mixture was stirred at room temperature for 6 hours. Upon completion of the reaction, the mixture was diluted with dichloromethane and neutralized with sodium bicarbonate. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The title compound (360 mg, 67% yield) was obtained by chromatographic purification. MSM / z: 609 [M+1].
[0859] Step 2) 4-(5-hydroxy-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol (360 mg) was dissolved in 4 mL of dichloromethane, and 4M hydrochloric acid-dioxane solution (4 mL) was slowly added dropwise at 0° C. The reaction mixture was stirred at room temperature for 1 hour. When the reaction was completed, the title compound was obtained by distillation under reduced pressure. MSM / z: 509 [M+1].
[0860] Step 3) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0861] The experimental method is the same as in Example 99, except that 4-(5-hydroxy-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1113 [M+1].
[0862] Example 104: N-(3-(2-((4-(4-(2-(2-(3-(4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0863] [ka]
[0864] Step 1) Preparation of 1-(2,4-dihydroxy-5-isopropylphenyl)ethan-1-one
[0865] To 4-isopropylbenzene-1,3-diol (121 mg, 0.80 mmol), boron trifluoride diethyl etherate (0.6 mL) was added, followed by acetic acid (48 mg, 0.80 Mol) at room temperature. The reaction mixture was stirred at 90°C for 4 hours. When the reaction was completed, an aqueous sodium acetate solution was added and stirred vigorously for 2.5 hours, and the solid obtained by filtration was dried to obtain the title compound. MSM / z: 195 [M+1].
[0866] Step 2) 1-(2,4-bis(benzyloxyl)-5-isopropylphenyl)ethan-1-one
[0867] 1-(2,4-dihydroxy-5-isopropylphenyl)ethan-1-one (115 mg, 0.59 mmol), benzyl bromide (236 mg, 1.38 mmol), potassium carbonate (204 mg, 1.48 mmol) and acetonitrile (2 mL) were added. The reaction mixture was stirred at 80°C for 12 hours. When the reaction was completed, acetonitrile was distilled under reduced pressure, water was added, and the solid formed was filtered and dried. Then, the title compound was obtained by wiping with hexane. MSM / z: 375 [M+1].
[0868] Step 3) 2,4-bis(benzyloxy)-5-isopropylbenzoic acid
[0869] 1-(2,4-bis(benzyloxyl)-5-isopropylphenyl)ethan-1-one (1.5 g, 4.01 mmol) and aqueous sodium hydroxide solution (1.60 g, 40.10 mmol) were dissolved in 1,4-dioxane (15 mL) / water (15 mL), and bromine (0.04 mL, 0.80 mmol) was slowly added dropwise. The reaction mixture was stirred at room temperature for 12 hours. When the reaction was completed, the pH was adjusted to 2 using aqueous hydrogen chloride solution, and the resulting solid was filtered, washed with water, and dried to obtain the title compound. 1H NMR (300MHz, DMSO-d6) δ7.57(s, 1H), 7.55-7.28(m, 10H), 6.89(s, 1H), 5.20(s, 4H), 3.24-3.13(m, 1H), 1.18-1.13(m, 6H). MSM / z:377[M+1].
[0870] Step 4) Preparation of (2,4-bis(benzyloxy)-5-isopropylphenyl)(5-bromoisoindolin-2-yl)methanone
[0871] 2,4-Bis(benzyloxy)-5-isopropylbenzoic acid (138mg, 0.37mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (140mg, 0.73mmol), and hydroxybenzotriazole (100mg, 0.74mmol) were dissolved in dimethylformamide (1.5mL). After stirring the reaction mixture at room temperature for 10 minutes, diisopropylethylamine (0.260mL, 1.47mmol) was added to the reaction mixture at 0℃, and 5-bromoisoindoline (95mg, 0.4mmol) was added slowly. The reaction mixture was stirred at room temperature for 8 hours. When the reaction was completed, the reaction mixture was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound (205mg, 64% yield) was obtained by chromatographic purification. 1H NMR (300MHz, DMSO-d6) δ7.64-7.18(m, 13H), 7.10(s, 1H), 6.96(s, 1H), 5.19(s, 4H), 4. 76(d, J=13.9, 2H), 4.51(d, J=16.3, 2H), 3.27-3.16(m, 1H), 1.16(s, 3H), 1.14(s, 3H). MSM / z:556[M+H].
[0872] Step 5) Preparation of benzyl 4-(methyltrifluoroborate)piperazine-1-carboxylate potassium salt
[0873] Benzylpiperazine-1-carboxylate (100 mg, 0.45 mmol) and potassium (bromomethyl)trifluoroborate (90 mg, 0.45 mmol) were dissolved in tetrahydrofuran (1.5 mL), and the mixture was stirred at 80° C. for 12 hours. After the reaction was completed, the reaction mixture was cooled and concentrated. Acetone and potassium carbonate were added to the concentrated reaction mixture, and the mixture was stirred for 30 minutes, filtered through Celite, and concentrated to obtain the title compound (116 mg, 76% yield). MSM / z: 301 [MK].
[0874] Step 6) Preparation of benzyl 4-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazine-1-carboxylate
[0875] (2,4-Bis(benzyloxy)-5-isopropylphenyl)(5-bromoisoindolin-2-yl)methanone (100mg, 0.18mmol), benzyl 4-(methyltrifluoroborate)piperazine-1-carboxylate potassium salt (61mg, 0.18mmol), XPhos (5mg, 0.011mmol), cesium carbonate (176mg, 0.54mmol) were added to a reaction vessel, and palladium acetate (1.2mg, 0.0054mmol) and a mixture of tetrahydrofuran (0.9mL) / water (0.1mL) were added under nitrogen. The reaction mixture was stirred at 80°C for 12 hours. After the reaction was completed, the mixture was filtered through Celite, and the filtrate was diluted with ethyl acetate and then wiped with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound (107mg, 84% yield) was obtained by chromatographic purification. MSM / z:710[M+H].
[0876] Step 7) Preparation of (2,4-dihydroxy-5-isopropylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone hydrochloride
[0877] Benzyl 4-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazine-1-carboxylate (100 mg, 0.25 mmol) and palladium hydroxide adsorbed on carbon (20 mg) were dissolved in a mixture of tetrahydrofuran (1 mL) / methanol (1 mL) and stirred for 12 hours while pressurizing with hydrogen. When the reaction was completed, the mixture was filtered through Celite and the filtrate was concentrated. The concentrated filtrate was diluted with ethyl acetate, 1N hydrochloric acid solution was added, and the filtered solid was wiped twice with ethyl acetate to obtain the title compound (80 mg, 74% yield). 1H NMR (300MHz, DMSO-d6) δ10.08(s, 1H), 7.35-7.14(m, 3H), 7.04(s, 1H), 6.39(s, 1H), 4.76(s, 4 H), 3.40(s, 2H), 3.15-3.03(m, 1H), 2.71-2.62(m, 4H), 2.26(s, 4H), 1.16(s, 3H), 1.14(s, 3H). MSM / z:396[M+H].
[0878] Step 8) N-(3-(2-((4-(4-(2-(2-(3-(4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0879] The experimental method was the same as in Example 99, except that (2,4-dihydroxy-5-isopropylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone was used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1002 [M+1].
[0880] Example 105: N-(3-(2-((4-(4-(2-(2-(3-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0881] [ka]
[0882] The experimental method was the same as in Example 99, except that (2,4-dihydroxy-5-isopropylphenyl)(5-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)isoindolin-2-yl)methanone was used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1099 [M+1].
[0883] Example 106: 2-amino-4-(2,4-dichloro-5-(2-(4-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
[0884] [ka]
[0885] Step 1) Preparation of N-(2,4-dichloro-5-hydroxyphenyl)acetamide
[0886] N-(3-hydroxyphenyl)acetamide (8g, 52.9mmol) was diluted with acetic acid (100mL) and then thionyl chloride (1.0M in MC, 111mL, 111mmol) was slowly added dropwise over 1 hour at room temperature. The reaction mixture was stirred at room temperature for 8 hours. When the reaction was completed, ice water was added and the resulting solid was filtered and washed with water. It was dried at 50℃ to obtain the title compound (yield 92%) in yellow.
[0887] Step 2) Preparation of N-(5-(benzyloxy)-2,4-dichlorophenyl)acetamide
[0888] N-(2,4-dichloro-5-hydroxyphenyl)acetamide (10g, 45.4mmol) and potassium carbonate (7.27g, 52.7mmol) were diluted with acetonitrile (100mL), and then benzyl bromide (7.765g, 45.4mmol) was slowly added dropwise. The reaction mixture was stirred at 80°C for 3 hours. When the reaction was completed, it was diluted with dichloromethane and wiped with brine, aqueous sodium hydroxide solution, and aqueous ammonium solution. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure to obtain the title compound (yield: 95%).
[0889] Step 3) 5-(benzyloxy)-2,4-dichloroaniline
[0890] N-(5-(benzyloxy)-2,4-dichlorophenyl)acetamide was dissolved in methanol (100 mL) / water (100 mL) / saturated hydrochloric acid (15 g, 0.15 Mol). The reaction mixture was stirred at 60° C. for 12 hours. When the reaction was completed, the solid was distilled under reduced pressure and filtered. It was wiped with water and dried at 50° C. to obtain the title compound (yield: 85%).
[0891] Step 4) Preparation of 1-(benzyloxyl)-2,4-dichloro-5-iodobenzene
[0892] Hydrogen chloride (60 mL, 6 M) in 5-(benzyloxy)-2,4-dichloroaniline
[0893] (16.2g, 60mmol) in acetic acid (240mL) was slowly added dropwise. Sodium nitrite (4.8g, 69mmol) aqueous solution (40mL) was slowly added dropwise at 5°C. The reaction mixture was stirred at the same temperature for 30 minutes, and then potassium iodide (20g, 120mmol), iodine (4g, 16mmol), and water (200mL) were added dropwise. The reaction mixture was stirred at the same temperature for 90 minutes. When the reaction was completed, it was diluted with dichloromethane and washed with water, sodium thiosulfate aqueous solution, sodium hydroxide aqueous solution, water, and salt water in that order. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure to obtain the title compound (yield: 90%).
[0894] Step 5) Ethyl 2-amino-4-(5-(benzyloxy)-2,4-dichlorophenyl)thieno[2,3-d]pyrimidine-6-carboxylate
[0895] 1-(Benzyloxyl)-2,4-dichloro-5-iodobenzene (20.6 g, 54 mmol), bis(pinacol)biboron (14.5 g, 57 mmol), potassium acetoxide (16 g, 163 mmol) were diluted with 50 mL of dimethylformamide, and palladium(II) acetate (450 mg, cat.) was added. The reaction mixture was stirred at 90° C. for 18 hours. Upon completion of the reaction, it was diluted with ethyl acetate and wiped with salt water. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure to obtain the title compound. 2-Amino-4-chloro-thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (12.85 g, 50 mmol), potassium phosphate aqueous solution (40 mL, 2 M) were added, and the mixture was diluted with 1,4-dioxane (160 mL). Palladium(II) acetate (450 mg, cat.) was added and the reaction mixture was stirred at 100° C. for 3 hours. Upon completion of the reaction, it was diluted with ethyl acetate and washed with brine. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure. The resulting residue was purified by chromatography to give the title compound (yield: 45%).
[0896] Step 6) 2-amino-4-(5-(benzyloxyl)-2,4-dichlorophenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
[0897] Ethyl 2-amino-4-(5-(benzyloxy)-2,4-dichlorophenyl)thieno[2,3-d]pyrimidine-6-carboxylate (500 mg, 1.05 mmol) was dissolved in tetrahydrofuran (4 mL) / methanol (4 mL) / water (4 mL) and lithium hydroxide (88 mg, 2.00 mmol) was added. After the reaction was completed, the mixture was diluted with ethyl acetate and wiped with 1N hydrogen chloride solution. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure and distilled under reduced pressure to obtain the title compound. HATU (798 mg, 2.10 mmol) and diisopropylethylamine (0.55 mL, 3.15 mmol) were added and stirred at room temperature for 30 minutes. Then, ethylamine (145 mg, 3.15 mmol) was slowly added dropwise. The reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was diluted with ethyl acetate and wiped with salt water. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure. The resulting residue was purified by chromatography to give the title compound (50%).
[0898] Step 7) 2-amino-4-(2,4-dichloro-5-hydroxyphenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
[0899] 2-Amino-4-(5-(benzyloxyl)-2,4-dichlorophenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide (280 mg, 0.59 mmol) was dissolved in 3 mL of dichloromethane, and then 3 mL of boron trichloride solution (1 M dichloromethane) was added slowly at -78°C. The reaction mixture was stirred at room temperature for 3 hours. When the reaction was completed, it was distilled under reduced pressure, diluted with ethyl acetate, and washed with aqueous sodium acetate and brine in that order. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The solid was produced using hexane, and filtered to obtain the title compound.
[0900] Step 8) tert-Butyl 4-(2-(5-(2-amino-6-(ethylcarbamoyl)thieno[2,3-d]pyrimidin-4-yl)-2,4-dichlorophenoxy)ethyl)piperazine-1-carboxylate
[0901] 2-Amino-4-(2,4-dichloro-5-hydroxyphenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide (500 mg, 1.05 mmol (88 mg, 0.23 mmol), triphenylphosphine (91 mg, 0.35 mmol), tert-butyl-4-(2-hydroxyethyl)piperazine-1-carboxylate (65 mg, 0.28 mmol) were dissolved in 10 mL of tetrahydrofuran. DEAD was then slowly added dropwise at room temperature, and the reaction mixture was stirred at room temperature for 3 hours. When the reaction was completed, it was diluted with ethyl acetate and washed with ammonium chloride aqueous solution and brine in that order. The resulting separated organic layer was dried over anhydrous sodium sulfate, filtered under reduced pressure, and distilled under reduced pressure. The resulting residue was purified by chromatography to obtain the title compound (55%).
[0902] Step 9) 2-amino-4-(2,4-dichloro-5-(2-(piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
[0903] tert-Butyl 4-(2-(5-(2-amino-6-(ethylcarbamoyl)thieno[2,3-d]pyrimidin-4-yl)-2,4-dichlorophenoxy)ethyl)piperazine-1-carboxylate (300 mg) was dissolved in 4 mL of ethyl acetate, and 4 mL of 4N hydrogen chloride in 1,4-dioxane was slowly added dropwise. The reaction mixture was stirred at room temperature for 4 hours. When the reaction was completed, the title compound (95%) was obtained by distillation under reduced pressure.
[0904] Step 10) 2-amino-4-(2,4-dichloro-5-(2-(4-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
[0905] The experimental method is the same as in Example 99, except that 2-amino-4-(2,4-dichloro-5-(2-(piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1048[M+1].
[0906] Example 107: N-(3-(2-((4-(4-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0907] [ka]
[0908] Step 1) Preparation of methyl 4-((4-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoate
[0909] The experimental procedure was the same except that methyl 4-(piperazin-1-ylmethyl)benzoate was used instead of benzylpiperazine-1-carboxylate in steps 5-6 of Example 104. MSM / z: 724 [M+1].
[0910] Step 2) 4-((4-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid
[0911] The experimental method was the same as that of Step 3 of Example 108. MSM / z: 709 [M+1].
[0912] Step 3) Preparation of 4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid
[0913] The experimental method was the same as in Step 4 of Example 108. MSM / z: 530 [M+1].
[0914] Step 4) N-(3-(2-((4-(4-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0915] 4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid (50 mg, 0.09 mmol), EDCI (54 mg, 0.28 mmol), HOAt (37 mg, 0.29 mmol) were dissolved in dimethylformamide (2 mL), and diisopropylethylamine (0.08 mL, 0.45 mmol) was added. The reaction mixture was stirred at room temperature for 30 minutes, and then N-(3-(2-((4-(piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide (46 mg, 0.10 mmol) was added, followed by stirring at 50 ° C for 6 hours. When the reaction was completed, the reaction mixture was diluted with dichloromethane and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. It was purified by chromatography to give the title compound. MSM / z: 976 [M+1].
[0916] Example 108: N-(3-(2-((4-(4-(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0917] [ka]
[0918] Step 1) Preparation of methyl 1-(methyltrifluoroborate)piperidine-4-carboxylate potassium salt
[0919] Methylpiperidine-4-carboxylate (100 mg, 0.70 mmol) and potassium (bromomethyl)trifluoroborate (141 mg, 0.70 mmol) were dissolved in tetrahydrofuran (2 mL), and the mixture was stirred at 80° C. for 12 hours. After the reaction was completed, the reaction mixture was cooled and concentrated. Acetone and potassium carbonate were added to the concentrated reaction mixture, and the mixture was stirred for 30 minutes, filtered through Celite, and concentrated to obtain the target compound (109 mg, 59% yield). MSM / z: 224 [MK].
[0920] Step 2) Preparation of methyl 1-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carboxylate
[0921] (2,4-Bis(benzyloxy)-5-isopropylphenyl)(5-bromoisoindolin-2-yl)methanone (100mg, 0.18mmol), methyl 1-(methyltrifluoroborate)piperidine-4-carboxylate potassium salt (47mg, 0.18mmol), XPhos (5mg, 0.011mmol), cesium carbonate (176mg, 0.54mmol) were added to a reaction vessel, and palladium acetate (1.2mg, 0.0054mmol) and a mixture of tetrahydrofuran (0.9mL) / water (0.1mL) were added under nitrogen. The reaction mixture was stirred at 80°C for 12 hours. After the reaction was completed, the mixture was filtered through Celite, and the filtrate was diluted with ethyl acetate and then wiped with salt water. The organic layer was dried over magnesium sulfate and concentrated. The target compound (49mg, 43% yield) was obtained by chromatographic purification. MSM / z:633[M+H].
[0922] Step 3) Preparation of 1-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carboxylate
[0923] Methyl 1-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carboxylate (660 mg, 1.0 mmol) was dissolved in a mixture of water (1 mL) / tetrahydrofuran (4 mL) / methanol (2 mL), and lithium hydroxide hydrate (130 mg, 3.1 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 2 hours, and then concentrated when the reaction was completed. The concentrated reaction mixture was diluted with water and dichloromethane, and 1N hydrochloric acid solution was added slowly to the reaction mixture to make the pH of the reaction mixture 4. The mixture was extracted three times with dichloromethane. The organic layer was collected, dried over sodium sulfate, and concentrated to obtain the target compound (590 mg, 92% yield). MSM / z 619 [M+H].
[0924] Step 4) Preparation of 1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carboxylate
[0925] Benzyl 1-((2-(2,4-bis(benzyloxy)-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperidine-4-carboxylate (155 mg, 0.25 mmol) and palladium hydroxide adsorbed on carbon (20 mg) were dissolved in a mixture of tetrahydrofuran (1 mL) / methanol (1 mL) and stirred for 12 hours under hydrogen pressure. Upon completion of the reaction, the mixture was filtered through Celite and the filtrate was concentrated to obtain the target compound (81 mg, 74% yield). MSM / z 439 [M+H].
[0926] Step 5) N-(3-(2-((4-(4-(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide
[0927] The experimental method was the same except that 1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carboxylate was used instead of 4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid in Example 107. MSM / z 885 [M+H].
[0928] Example 109: 4-(2-(2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffeine-8-yl)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0929] [ka]
[0930] (2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolan-1(1,4)-benzenecycloundecaffeine (83 mg, 0.22 mmol), potassium iodide (219 mg, 0.66 mmol), diisopropylethylamine (0.12 mL, 0.66 mmol) and 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol) were dissolved in dimethylformamide (2 mL). The reaction mixture was stirred at 60°C for 12 hours. When the reaction was complete, the reaction mixture was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound (75 mg, 51% yield) was obtained by chromatographic purification. MSM / z:676[M+1].
[0931] Example 110: 4-(3-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffeine-8-yl)propoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0932] [ka]
[0933] The experimental method was the same as in Example 109, except that 4-(3-bromopropoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol). MSM / z: 690 [M+1].
[0934] Example 111: 4-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffeinated-8-yl)ethoxy)ethoxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione
[0935] [ka]
[0936] The experimental method was the same as in Example 109, except that 4-(2-(2-bromoethoxy)ethoxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol). MSM / z: 706 [M+1].
[0937] Example 112: 4-((6-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffeinated-8-yl)hexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0938] [ka]
[0939] The experimental method was the same as in Example 109, except that 4-((6-bromohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol). MSM / z: 732 [M+1].
[0940] Example 113: 4-((8-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffeine-8-yl)octyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0941] [ka]
[0942] The experimental method was the same as in Example 109, except that 4-((8-bromooctyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol). MSM / z: 690 [M+1].
[0943] Example 114: 4-((8-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffeine-8-yl)octyl)oxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione
[0944] [ka]
[0945] The experimental method was the same as in Example 109, except that 4-((8-bromooctyl)oxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol). MSM / z: 746 [M+1].
[0946] Example 115: 4-((11-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffeine-8-yl)undecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0947] [ka]
[0948] The experimental method was the same as in Example 109, except that 4-((11-bromoundecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol). MSM / z: 802 [M+1].
[0949] Example 116: 4-((9-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolan-1(1,4)-benzenecycloundecaffeine-8-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dioneundecaffeine
[0950] [ka]
[0951] The experimental method was the same as in Example 109, except that 4-((9-bromononyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was used instead of 4-(2-bromoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (167 mg, 0.44 mmol). MSM / z: 774 [M+1].
[0952] Example 117: 5-(4-((1-(3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffeinated-8-yl)ethoxy)ethoxy)propanoyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione
[0953] [ka]
[0954] Step 1) t-Butyl 3-(2-(2-((2 1 Z,4 4 E)-4 1 Preparation of H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoic acid
[0955] N(2 1 Z,4 4 E)-4 1H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffeine (83 mg, 0.22 mmol), potassium iodide (73 mg, 0.22 mmol), diisopropylethylamine (0.12 mL, 0.66 mmol) and t-butyl 3-(2-(2-iodoethoxy)ethoxy)propanoate (151 mg, 0.44 mmol) were dissolved in dimethylformamide (2 mL). The reaction mixture was stirred at 60° C. for 24 hours. When the reaction was complete, the reaction mixture was diluted with ethyl acetate and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound was purified by chromatography to obtain (66 mg, 51% yield). MSM / z: 592 [M+1].
[0956] Stage 2) 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffeinated-8-yl)ethoxy)ethoxy)propanoic acid
[0957] t-Butyl 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoic acid (90 mg, 0.17 mmol) was dissolved in tetrahydrofuran (1 mL), methanol (1 mL), and water (1 mL), and LiOH-H2O (15 mg, 0.34 mmol) was added. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with ethyl acetate, neutralized with 1N aqueous hydrogen chloride solution to pH 5, and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated to give the title compound (92 mg, 94% yield). It was used in the next reaction without purification. MSM / z: 536 [M+1].
[0958] Stage 3) 5-(4-((1-(3-(2-(2-((2 1 Z,4 4 E)-4 1 Preparation of H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecane-8-yl)ethoxy)ethoxy)propanoyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione
[0959] 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffeine-8-yl)ethoxy)ethoxy)propanoic acid (55 mg, 0.10 mmol), EDCI (56 mg, 0.29 mmol), and HOAt (40 mg, 0.29 mmol) were dissolved in dimethylformamide (2 mL), and then diisopropylethylamine (0.08 mL, 0.49 mmol) was added. The reaction mixture was stirred at room temperature for 30 minutes, and then 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione (50 mg, 0.11 mmol) was added and stirred at 50° C. for 6 hours. Upon completion of the reaction, the reaction mixture was diluted with dichloromethane and washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound was obtained by chromatographic purification. MSM / z: 976 [M+1].
[0960] Example 118: 3-(2-(2-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)propanamide
[0961] [ka]
[0962] The experimental method is the same as that of Example 117, except that 4-(4-(4-(3-aminopropoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 903 [M+1].
[0963] Example 119: 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)propanamide
[0964] [ka]
[0965] The experimental method was the same as in Example 117, except that 2-amino-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)acetamide was used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 960 [M+1].
[0966] Example 120: 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)propan-1-one
[0967] [ka]
[0968] The experimental method is the same as that of Example 117, except that 4-(5-hydroxy-4-(4-(piperazin-1-ylmethyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 928 [M+1].
[0969] Example 121: 3-(2-(2-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one
[0970] [ka]
[0971] The experimental method is the same as that of Example 117, except that 4-(5-hydroxy-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1025 [M+1].
[0972] Example 122: 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)propan-1-one
[0973] [ka]
[0974] The experimental method is the same as that of Example 117, except that (2,4-dihydroxy-5-isopropylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 914 [M+1].
[0975] Example 123: 3-(2-(2-((2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one
[0976] [ka]
[0977] The experimental method was the same as in Example 117, except that (2,4-dihydroxy-5-isopropylphenyl)(5-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)isoindolin-2-yl)methanone was used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1011 [M+1].
[0978] Example 124: 4-(5-(2-(4-(3-(2-(2-((2 1 Z,4 4 E)-4 1H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffeinated-8-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)-2,4-dichlorophenyl)-2-amino-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
[0979] [ka]
[0980] The experimental method is the same as that of Example 117, except that 2-amino-4-(2,4-dichloro-5-(2-(piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione. MSM / z: 1014[M+1].
[0981] Example 125: ((2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)phenyl)methanone
[0982] [ka]
[0983] 4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid (50 mg, 0.09 mmol), EDCI (54 mg, 0.28 mmol), and HOAt (37 mg, 0.29 mmol) were dissolved in dimethylformamide (2 mL), and then diisopropylethylamine (0.08 mL, 0.45 mmol) was added. The reaction mixture was stirred at room temperature for 30 minutes, and then (2 1 Z,4 4 E)-4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine (38 mg, 0.10 mmol) was added and stirred at 50°C for 6 hours. When the reaction was completed, the reaction mixture was diluted with dichloromethane and then washed with salt water. The organic layer was dried over magnesium sulfate and concentrated. The title compound was obtained by chromatographic purification. MSM / z: 888 [M+1].
[0984] Example 126: ((2 1 Z,4 4 E)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazolac-1(1,4)-benzenecycloundecaffeinated-8-yl)(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidin-4-yl)methanone
[0985] [ka]
[0986] The experimental method was the same as in Example 125, except that 1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carboxylate was used instead of 4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid. MSM / z: 796 [M+1].
[0987] The structures and LC-MS of Examples 1 to 126 are summarized in the table below.
[0988] [Table 1]
[0989] [Table 2]
[0990] [Table 3]
[0991] [Table 4]
[0992] [Table 5]
[0993] [Table 6]
[0994] [Table 7]
[0995] [Table 8]
[0996] [Table 9]
[0997] [Table 10]
[0998] [Table 11]
[0999] [Table 12]
[1000] [Table 13]
[1001] [Table 14]
[1002] [Table 15]
[1003] [Table 16]
[1004] Meanwhile, the novel compound represented by Formula 1 according to the present invention can be formulated in various forms according to the purpose. The following are examples of some formulation methods containing the compound represented by Formula 1 according to the present invention as an active ingredient, but the present invention is not limited thereto.
[1005] [Formulation example]
[1006] Formulation Example 1: Tablets (direct compression)
[1007] 5.0 mg of active ingredient was sieved, mixed with 14.1 mg lactose, 0.8 mg crospovidone USNF and 0.1 mg magnesium stearate and compressed into tablets.
[1008] Formulation Example 2: Tablets (wet assembly)
[1009] 5.0mg of active ingredient was sieved, then mixed with 16.0mg lactose and 4.0mg starch. 0.3mg polysorbate 80 was dissolved in pure water, then an appropriate amount of this solution was added, and then granulated. After drying, the granules were sieved, then mixed with 2.7mg colloidal silicon dioxide and 2.0mg magnesium stearate. The granules were compressed to form tablets.
[1010] Formulation example 3: Powder and capsules
[1011] 5.0 mg of the active ingredient was sieved and then mixed with 14.8 mg of lactose, 10.0 mg of polyvinylpyrrolidone, and 0.2 mg of magnesium stearate. The mixture was filled into No. 5 hard gelatin capsules using a suitable device.
[1012] Formulation Example 4: Injection
[1013] An injection was prepared containing 100 mg of the active ingredient, as well as 180 mg of mannitol, 26 mg of Na2HPO412H2O, and 2974 mg of distilled water.
[1014] [Experimental Example]
[1015] Experimental example 1. Measurement of enzyme activity in cancer cells
[1016] 3000 cells were dispensed into each well of a 96-well plate. After stabilization of the cells, the compounds were treated with 1 / 3 serial dilutions to 0.5% DMSO and cultured for 72 hours. When Cell titerglo was treated, luciferase decomposed luciferin and luminescence was emitted only in the presence of ATP. Luminescence values were measured using Envision (PerkinElmer). The GI50 value was calculated by calculating the concentration of the compound that caused cell death based on the measured luminescence values.
[1017] The experimental results were the same as those in Table 1 below. Activity values were expressed in three levels.
[1018] A:IC 50 <1 μM
[1019] B: 1μM or less IC 50 <10 μM
[1020] C:IC 50 ≥ 10 μM
[1021] [Table 17]
[1022] Experimental Example 2. Measurement of enzyme activity in Ba / F3 cells
[1023] 3000 cells were dispensed into each well of a 96-well plate. After stabilization of the cells, the compounds were treated with 1 / 3 serial dilutions to 0.5% DMSO and cultured for 72 hours. When Cell titerglo was treated, luciferase decomposed luciferin and luminescence was emitted only in the presence of ATP. Luminescence values were measured using Envision (PerkinElmer). The GI50 value was calculated by calculating the concentration of the compound that caused cell death based on the measured luminescence values.
[1024] The experimental results were the same as those in Table 2 below. Activity values were expressed in three levels.
[1025] A:IC 50 <1 μM
[1026] B: 1μM or less IC 50 <10 μM
[1027] C:IC 50 ≥ 10 μM
[1028] [Table 18]
[1029] Experimental example 3. Measurement of target protein degradation in cancer cells
[1030] 1x10 per well of a 6-well plate 6 Dispense 1000 cells into each well, treat with compounds at different concentrations, and incubate for 24 hours. After cell lysis, perform BCA assay to measure protein, add Laemmli sample buffer (reducing), and boil at 99℃ for 5 minutes to prepare samples for Western blotting.
[1031] The samples were loaded onto an acrylamide gel and electrophoresis was carried out, after which the proteins were transferred to the membrane via transfer. After stirring for 30 minutes with 5% skim milk to prevent non-specific binding between the antibody and protein, the membrane was stirred for 10 hours at 4℃ with a solution of the primary antibody diluted 1:1000. The membrane was washed three times for 5 minutes with TBS / T buffer to remove any primary antibody that was not bound to the membrane. The membrane was stirred for 1 hour at room temperature with a solution of the secondary antibody conjugated with HRP (horse radish peroxidase) diluted 1:10000. The membrane was washed three times for 5 minutes with TBS / T buffer to remove any secondary antibody that was not bound to the membrane. After treatment with ECL solution, chemiluminescence was measured using LAS.
[1032] The experimental results were the same as in FIG.
Claims
1. A 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by the following chemical formula 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Formula 1] In the above Chemical Formula 1, R 1 , R 2 and R 3 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); ester group (-C(O)OR 8 ); carboxylic acid group (-C(O)OH); nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; A and B are each independently C 6 -C 10 Aryl group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heteroaryl group; or C 3 -C 10 a heterocyclyl group; R 4 , R 5 , R 6 and R 7are each independently a hydrogen atom; a hydroxyl group; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Haloalkyl; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; L a is a hydrogen atom; a hydroxyl group; a halogen group; C 1 -C 13 Alkyl group; -Z a -Q 3 -E; or -Z a -Q 1 -M; and -Z a -Q 1 -M, M is L b Ga-Z b -Q 2 When Q 2 is linked to form a ring, L b is a hydrogen atom; a hydroxyl group; a halogen group; C 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3-C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or -Z b -Q 2 and said -Z b -Q 2 So, Q. 2 L a Ga-Z a -Q 1 -M, which is linked to M to form a ring; Said Z a Or Z b may or may not exist independently, Z a Or Z b If there is Z a Or Z b are each independently -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 ) -, -(C n H n+2 ) O-, -(C n H n+2 ) O(C m H m+2 ) -, -C 3 -C 10 Cyclyl group -; or -C 3 -C 10 a heterocyclyl group -; Q 1 , Q 2 and Q. 3 are each independently -C n H n+2-, -O(C n H n+2 ) -, -(OC 2 H 4 ) n -, -(C 2 H 4 O) n -, -(C n H n+2 ) O-, -(C n H n+2 )CO-, -NR 8 (C n H n+2 ) -, -(NR 8 C 2 H 4 ) n -, -(C 2 H 4 N.R. 8 ) n -, -(C n H n+2 ) N.R. 8 -, -(C n H n+2 ) O(C m H m+2 ) -, -(C n H n+2 ) O(C m H m+2 ) CO-, -C 3 -C 10 Cyclyl group -; or -C 3 -C 10 a heterocyclyl group -; Q 4 is either present or absent, if present, -C n H n+2 -, -C n H n - or -C n H n-2 - and The M is —O—, —CO—, —COO—, —C 2 H 2 -, -C n H n+2 -, -O(C n H n+2 ) -, -(C n H n+2 ) O-, -(C n H n+2 ) O(C m H m+2 ) -, -NR 8 -;-NR 8 CH 2 -;-NHR 8 -;-NR 8 C(O)-; -NR 8 C(O)O-;-C(O)NR 8 -;-NR 8 C(O)NR 8 -;-NC(O)R 8 -;-NS(O) 2 R8-; -S(O) 2 -;-NR 8 S (O) 2 -; and -S(O) 2 N.R. 8 -; and n and m each independently represent an integer of 0 to 15; The E is [Case 2] or [C3] and The X 2 , X 3 and X 4 are each independently hydrogen; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Haloalkyl; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; The X 1 Is there or not, if there is, X 1 is -CR 8 R 9 -, -O- or -NR 8 - and The Y 1 , Y 2 , Y 3 and Y 4 are each independently C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl group; C 3 -C 10 A cyclyl group; or C 3 -C 10 a heterocyclyl group; The R 8 and R 9 are each independently hydrogen; 1 -C 6 Alkyl group; C 1 -C 6 Alkenyl group; C 1 -C 6 Alkynyl group; C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl group; C 3 -C 10 Cyclyl group; C 3 -C 10 heterocyclyl group; or R 8 is R 9 Together with the nitrogen or carbon atom linked to N, O, S, NH, C═N, C═O, —NHC(O)—, —NHC(O)NH—, —NHS(O) 2 - or SO 2 At least one of hydrogen, C 1 -C 13 Alkyl group, C 6 -C 10Aryl group, C 3 -C 10 forming a 3- to 7-membered saturated ring optionally substituted with at least one of a heteroaryl group, a hydroxyl group, a halide group, and a cyano group; Said C 1 -C 6 Alkoxy group, C 1 -C 13 Alkyl group or C 3 -C 10 The cyclyl group is selected from the group consisting of hydrogen, hydroxyl, halogen, and C. 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ), carboxylic acid group (-C(O)OH); -ester group (-C(O)OR 8 ), nitrile group (-CN); urea group (-NR 8 (C=O)NR 9 -); sulfonamide group (-NHS(O) 2 -); sulfide group (-S-); sulfone group (-S(O) 2 -); phosphoryl group (-P(O)R 8 R 9 ); C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl groups; and C 3 -C 10 one or more substituents selected from the group consisting of heterocyclyl groups; Said C 6 -C 10 Aryl group, C 3 -C 10 Heteroaryl group or C 3 -C 10 Heterocyclyl groups include hydrogen, hydroxyl groups, halogen groups, and carbonyl groups (-(C=O)R 8 R 9 ); halogen or C 3 -C 10C substituted or unsubstituted with a heterocyclyl group 1 -C 3 Alkyl group; halogen or C 3 -C 10 C substituted or unsubstituted with a heterocyclyl group 1 -C 3 Alkoxy group; C 6 -C 10 Phenoxy; Amino group (-NR 8 R 9 ); an amide group (-(C=O)NR 8 R 9 ); C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl groups and C 3 -C 10 one or more substituents selected from the group consisting of heterocyclyl groups; Said C 3 -C 10 Heteroaryl groups and C 3 -C 10 The heterocyclyl group contains one or more heteroatoms selected from the group consisting of N, O, and S.
2. The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by chemical formula 1 according to claim 1, wherein A and B are each independently furan, benzofuran, pyrrole, indole, thiophene, benzothiophene, imidazole, benzimidazole, purine, pyrazole, indazole, oxazole, benzoxazole, thiazole, benzothiazole, benzene, naphthalene, anthracene, pyridine, quinoline, pyrazine, quinoxaline, acridine, pyrimidine, quinazoline, pyridazine, cinnoline, phthalazine, or triazine, a pharma- ceutically acceptable salt, hydrate, or solvate thereof.
3. A and B are each independently benzene, pyrazole, pyridine, indazole, pyrimidine, quinoline, or thiazole; The R 1 , R 2 and R 3are each independently hydrogen, a halogen group, or C 1 -C 13 Alkyl group or C 3 -C 10 A 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1 according to claim 1, which is a cyclyl group, a pharma- ceutically acceptable salt thereof, a hydrate thereof or a solvate thereof.
4. The R 4 , R 5 , R 6 and R 7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 3 ;-NHMs;-CO(NH)CH 3 ;-OCH 3 ;-OC 2 H 5 or -OC 6 H 12 COOCH 3 2. The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1 according to claim 1, wherein:
5. The compound is represented by the following formula 2: [C4] In the above Chemical Formula 2, R 1 , R 2 and R 3 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); ester group (-C(O)OR 8 ); carboxylic acid group (-C(O)OH); nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; A and B are each independently C 6 -C 10 Aryl group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heteroaryl group; or C 3 -C 10 a heterocyclyl group; R 4 , R 5 , R 6 and R 7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Haloalkyl; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8); or a phosphoryl group (-P(O)R 8 R 9 ) ; L b is a hydrogen atom; a hydroxyl group; a halogen group; C 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); or a sulfone group (-S(O) 2 R 8 ) ; Said Z a Is there, or is there not, Z a If there is Z a is -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 ) -, -(C n H n+2 ) O-, -(C n H n+2 ) O(C m H m+2 ) -, -C 3 -C 10 Cyclyl group -; or -C 3 -C 10 a heterocyclyl group -; Q 3 is -C n H n+2 -, -O(C n H n+2 ) -, -(OC 2 H 4 ) n-, -(C 2 H 4 O) n -, -(C n H n+2 ) O-, -(C n H n+2 )CO-, -NR 8 (C n H n+2 ) -, -(NR 8 C 2 H 4 ) n-, -(C 2 H 4 N.R. 8 ) n -, -(C n H n+2 ) N.R. 8 -, -(C n H n+2 ) O(C m H m+2 ) -, -(C n H n+2 ) O(C m H m+2 ) CO-, -C 3 -C 10 Cyclyl group -; or -C 3 -C 10 a heterocyclyl group -; Q 4 is either present or absent, if present, -C n H n+2 -, -C n H n - or -C n H n-2 - and n and m each independently represent an integer of 0 to 15; The E is [C5] or [C6] and The X 2 , X 3 and X 4 are each independently hydrogen; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Haloalkyl; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; The X 1 Is there or not, if there is, X 1 is -CR 8 R 9 -, -O- or -NR 8 - and The Y 1 , Y 2 , Y 3 and Y 4 are each independently C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl group; C 3 -C 10 A cyclyl group; or C 3 -C 10 a heterocyclyl group; The R 8 and R 9 are each independently hydrogen; 1 -C 6 Alkyl group; C 1 -C 6 Alkenyl group; C 1 -C 6 Alkynyl group; C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl group; C 3 -C 10 Cyclyl group; C 3 -C 10 heterocyclyl group; or R 8 is R 9 Together with the nitrogen or carbon atom linked to N, O, S, NH, C═N, C═O, —NHC(O)—, —NHC(O)NH—, —NHS(O) 2 - or SO 2 At least one of hydrogen, C 1 -C 13 Alkyl group, C 6 -C 10 Aryl group, C 3 -C 10 forming a 3- to 7-membered saturated ring optionally substituted with at least one of a heteroaryl group, a hydroxyl group, a halide group, and a cyano group; Said C 1 -C 6 Alkoxy group, C 1 -C 13 Alkyl group or C 3 -C 10 The cyclyl group is selected from the group consisting of hydrogen, hydroxyl, halogen, and C. 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ), carboxylic acid group (-C(O)OH); -ester group (-C(O)OR 8 ), nitrile group (-CN); urea group (-NR 8 (C=O)NR 9 -); sulfonamide group (-NHS(O) 2 -); sulfide group (-S-); sulfone group (-S(O) 2 -); phosphoryl group (-P(O)R 8 R 9); C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl groups; and C 3 -C 10 one or more substituents selected from the group consisting of heterocyclyl groups; Said C 6 -C 10 Aryl group, C 3 -C 10 Heteroaryl group or C 3 -C 10 Heterocyclyl groups include hydrogen, hydroxyl groups, halogen groups, and carbonyl groups (-(C=O)R 8 R 9 ); halogen or C 3 -C 10 C substituted or unsubstituted with a heterocyclyl group 1 -C 3 Alkyl group; halogen or C 3 -C 10 C substituted or unsubstituted with a heterocyclyl group 1 -C 3 Alkoxy group; C 6 -C 10 Phenoxy; Amino group (-NR 8 R 9 ); an amide group (-(C=O)NR 8 R 9 ); C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl groups and C 3 -C 10 one or more substituents selected from the group consisting of heterocyclyl groups; Said C 3 -C 10 Heteroaryl groups and C 3 -C 10 The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by chemical formula 1 according to claim 1, wherein the heterocyclyl group contains one or more heteroatoms selected from the group consisting of N, O, and S, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
6. In the above Chemical Formula 2, A and B are each independently benzene, pyrazole, pyridine, indazole, pyrimidine, quinoline, or thiazole; The R 1 , R 2 and R 3 are each independently hydrogen, a halogen group, or C 1 -C 13 Alkyl group or C 3 -C 10 is a cyclyl group, The R 4 , R 5 , R 6 and R 7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 3 ;-NHMs;-CO(NH)CH 3 ;-OCH 3 ;-OC 2 H 5 or -OC 6 H 12 COOCH 3 and The Y 1 teeth, [C7] and Y a and Y b are each independently hydrogen; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Haloalkyl; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; Y c and Y d are each independently -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 ) -, -(C n H n+2 ) O-, -(C n H n+2 ) O(C m H m+2 ) -, -C 3 -C 10 Cyclyl group -; or -C 3 -C 10 a heterocyclyl group -; Y e is C 6 -C 10 Aryl group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heteroaryl group; or C 3 -C 10 A 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1 according to claim 5, wherein R is a heterocyclyl group; a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
7. In the above Chemical Formula 2, E is the following E 1 , E 2 , E 3 , E 4 , E 5 , E 6 , E 7 , E 8 , E 9 , E 10 , E 11 , E 12 , E 13 , E 14 Or E 15 That is, [C8] A 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1 according to claim 5, a pharma- ceutically acceptable salt thereof, a hydrate thereof or a solvate thereof.
8. The compound is represented by the following formula 3: [C9] In the above Chemical Formula 3, R 1 , R 2 and R 3 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); ester group (-C(O)OR 8 ); carboxylic acid group (-C(O)OH); nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; A and B are each independently C 6 -C 10 Aryl group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heteroaryl group; or C 3 -C 10 a heterocyclyl group; R 4 , R 5 , R 6 and R 7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8 ); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; Said Z a Or Z b may or may not exist independently, Z a Or Z b If there is Z a Or Z b are each independently -O-, -CO-, -COO-, -C n H n+2 -, -O(C n H n+2 ) -, -(C n H n+2 ) O-, -(C n H n+2 ) O(C m H m+2 ) -, -C 3 -C 10 Cyclyl group -; or -C 3 -C 10 a heterocyclyl group -; Q 1 and Q. 2 are each independently -C n H n+2 -, -O(C n H n+2 ) -, -(OC 2 H 4 ) n -, -(C 2 H 4 O) n -, -(C n H n+2 ) O-, -(C n H n+2 )CO-, -NR 8 (C n H n+2 ) -, -(NR 8 C 2 H 4 ) n -, -(C 2 H 4 N.R. 8 ) n -, -(C n H n+2 ) N.R. 8 -, -(C n H n+2 ) O(C m H m+2 ) -, -(C n H n+2 ) O(C m H m+2 ) CO-, -C 3 -C 10 Cyclyl group -; or -C 3 -C 10 a heterocyclyl group -; The M is —O—, —CO—, —COO—, —C 2 H 2 -, -C n H n+2 -, -O(C n H n+2 ) -, -(C n H n+2 ) O-, -(C n H n+2 ) O(C m H m+2 ) -, -NR 8 -;-NR 8 CH 2 -;-NHR 8 -;-NR 8 C(O)-; -NR 8 C(O)O-;-C(O)NR 8 -;-NR 8 C(O)NR 8 -;-NC(O)R 8 -;-NS(O) 2 R 8 -;-S(O) 2 -;-NR 8 S (O) 2 -; and -S(O) 2 N.R. 8 -; and The E is [C10] or [C11] and The X 2 , X 3 and X 4 are each independently hydrogen; a halogen group; 1 -C 13 Alkyl group; C 1 -C 6 Haloalkyl; C 1 -C 6 Alkoxy group; C 3 -C 10 Cyclyl group; C 3 -C 10 Heterocyclyl group; -C(O)-(C 1 -C 13 alkyl group); amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ); carboxylic acid group (-C(O)OH); ester group (-C(O)OR 8 ), nitrile group (-CN); sulfonamide group (-NHS(O) 2 R 8 ); sulfide group (-SR 8); sulfone group (-S(O) 2 R 8 ); or a phosphoryl group (-P(O)R 8 R 9 ) ; The X 1 Is there or not, if there is, X 1 is -CR 8 R 9 -, -O- or -NR 8 - and The Y 1 , Y 2 , Y 3 and Y 4 are each independently C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl group; C 3 -C 10 A cyclyl group; or C 3 -C 10 a heterocyclyl group; The R 8 and R 9 are each independently hydrogen; 1 -C 6 Alkyl group; C 1 -C 6 Alkenyl group; C 1 -C 6 Alkynyl group; C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl group; C 3 -C 10 Cyclyl group; C 3 -C 10 heterocyclyl group; or R 8 is R 9 Together with the nitrogen or carbon atom linked to N, O, S, NH, C═N, C═O, —NHC(O)—, —NHC(O)NH—, —NHS(O) 2 - or SO 2 At least one of hydrogen, C 1 -C 13 Alkyl group, C 6 -C 10 Aryl group, C 3 -C 10 forming a 3- to 7-membered saturated ring optionally substituted with at least one of a heteroaryl group, a hydroxyl group, a halide group, and a cyano group; Said C 1 -C 6 Alkoxy group, C 1 -C 13 Alkyl group or C 3 -C 10 The cyclyl group is selected from the group consisting of hydrogen, hydroxyl, halogen, and C. 1 -C 13 Alkyl group; C 1 -C 6 Alkoxy group; amino group (-NR 8 R 9 ), nitro group (-N(O) 2 ); an amide group (-(C=O)NR 8 R 9 ), carboxylic acid group (-C(O)OH); -ester group (-C(O)OR 8 ), nitrile group (-CN); urea group (-NR 8 (C=O)NR 9 -); sulfonamide group (-NHS(O) 2 -); sulfide group (-S-); sulfone group (-S(O) 2 -); phosphoryl group (-P(O)R 8 R 9 ); C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl groups; and C 3 -C 10 one or more substituents selected from the group consisting of heterocyclyl groups; Said C 6 -C 10 Aryl group, C 3 -C 10 Heteroaryl group or C 3 -C 10 Heterocyclyl groups include hydrogen, hydroxyl groups, halogen groups, and carbonyl groups (-(C=O)R 8 R 9 ); halogen or C 3 -C 10 C substituted or unsubstituted with a heterocyclyl group 1 -C 3 Alkyl group; halogen or C 3 -C 10 C substituted or unsubstituted with a heterocyclyl group 1 -C 3 Alkoxy group; C 6 -C 10 Phenoxy; Amino group (-NR 8 R 9 ); an amide group (-(C=O)NR 8 R 9 ); C 6 -C 10 Aryl group; C 3 -C 10 Heteroaryl groups and C 3 -C 10 one or more substituents selected from the group consisting of heterocyclyl groups; Said C 3 -C 10 Heteroaryl groups and C 3 -C 10 The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by chemical formula 1 according to claim 1, wherein the heterocyclyl group contains one or more heteroatoms selected from the group consisting of N, O, and S, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
9. In the above Chemical Formula 3, A and B are each independently benzene, pyrazole, pyridine, indazole, pyrimidine, quinoline, or thiazole; The R 1 , R 2 and R 3 are each independently hydrogen, a halogen group, or C 1 -C 13 Alkyl group or C 3 -C 10 is a cyclyl group, The R 4 , R 5 , R 6 and R 7 are each independently a hydrogen atom; a hydroxyl group; a halogen group; 3 ;-NHMs;-CO(NH)CH 3 ;-OCH 3 ;-OC 2 H 5 or -OC 6 H 12 COOCH 3 9. The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1 according to claim 8, wherein:
10. In the above Chemical Formula 3, E is the following E 1 , E 2 , E 3 , E 4 , E 5 , E 6 , E 7 , E 8 , E 9 , E 10 , E 11 , E 12 , E 13 , E 14 Or E 15 That is, [C12] A 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1 according to claim 8, a pharma- ceutically acceptable salt thereof, a hydrate thereof or a solvate thereof.
11. The compound is a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by formula 1 according to claim 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein the compound is selected from the group consisting of the following compound numbers 1 to 126: (Compound No. 1) (2 1 Z, 4 4 E) -4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 2) ((2 1 Z, 4 4 E) -8-methyl-4 1H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 3) 1-((2 1 Z, 4 4 E) -4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecycloundecaffein-8-yl)ethan-1-one; (Compound No. 4) 1-((2 1 Z, 4 4 E) -4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)butan-1-one; (Compound No. 5) ((2 1 Z, 4 4 E) -4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(4-chlorophenyl)methanone; (Compound No. 6) (2 1 Z, 4 4 E) -N-cyclohexyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide; (Compound No. 7) (2 1 Z, 4 4 E) -N-(3-methoxyphenyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide; (Compound No. 8) (2 1 Z, 4 4E) -N-ethyl-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-carboxamide; (Compound No. 9) (2 1 Z, 4 4 E) -8-(methylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 10) (2 1 Z, 4 4 E) -8-((3,4-difluorophenyl)sulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 11) (2 1 Z, 4 4 E) -8-(phenylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 12) (2 1 Z, 4 4 E) -8-(cyclopropylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 13) (2 1 Z, 4 4 E) -8-(propylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 14) (2 1Z, 4 4 E) -8-((5-chlorothiophen-2-yl)sulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 15) (2 1 Z, 4 4 E) -8-(cyclohexylsulfonyl)-4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine; (Compound No. 16) (Z)-5-oxa-3,9,15-triazine-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one; (Compound No. 17) (1 4 Z, 2 1 Z)-1 1 H-5-oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1(4,1)-pyrazo-4(1,4)-benzenecyclohexadecapan-10-one; (Compound No. 18) (1 4 Z, 2 1 Z, 4 4 E) -1 1 H, 4 1 H-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(4,1)-dipyrazolacylpentadecapan-9-one; (Compound No. 19) (1 4 Z, 2 1 Z)-1 1 H-3-Aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1(4,1)-pyrazo-4(1,4)-benzenecyclododecapan-9-one; (Compound Number 20) (Z)-13-fluoro-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one; (Compound No. 21) (2 1 Z, 4 4 E) -13-fluoro-4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclohexadecapan-9-one; (Compound No. 22) (Z)-1 3 -fluoro-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one; (Compound No. 23) (Z)-17-oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one; (Compound No. 24) (Z)-13-oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(1,4)-piperazine-1,4(1,4)-dibenzenecyclotridecapan-6-one; (Compound No. 25) (2 1 Z, 4 4 E) -4 1 H-11-Oxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecapan-6-one; (Compound No. 26) (2 1 Z, 4 4 E) -4 1 H-15-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidin-4(4,1)-pyrazola-1(1,4)-benzenecyclopentadecapan-10-one; (Compound No. 27) (2 1Z, 4 4 E) -4 1 H-17-Oxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-5(4,1)-piperidin-4(4,1)-pyrazo-1(1,4)-benzenecycloheptadecapan-10-one; (Compound No. 28) (Z)-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one; (Compound No. 29) (Z)-5,17-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecycloheptadecapan-10-one; (Compound No. 30) (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecaffeine; (Compound Number 31) (Z)-1-(5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl)propan-1-one; (Compound No. 32) (Z)-5,12-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclododecapan-9-yl(4-chlorophenyl)methanone; (Compound No. 33) (2 1 Z,7Z)-5,10-dioxa-3-aza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclodecapan-7-ene; (Compound No. 34) (Z)-4 2 -Methoxy-5,12,15-trioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one; (Compound No. 35) (2 1 Z, 4 4 E) -4 1H-11,14-dioxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecyclotetradecapan-9-one; (Compound No. 36) (2 1 Z, 4 4 E) -4 1 H-14-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecyclotetradecapan-9-one; (Compound No. 37) (2 1 Z, 4 4 E) -4 1 H-16-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazo-1(1,4)-benzenecyclohexadecapan-9-one; (Compound No. 38) (Z)-5,15-dioxa-3,9-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-1,4(1,4)-dibenzenecyclopentadecapan-10-one; (Compound No. 39) N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 40) N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)propyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 41) N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 42) N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 43) N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 44) N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)butyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 45) N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 46) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 47) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 48) N-(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 49) N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 50) N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 51) N-(3-(2-((4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 52) N-(3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 53) 3-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-N-methylbenzamide; (Compound Number 54) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-phenylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione; (Compound Number 55) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione; (Compound Number 56) 4-((9-(4-(4-((7-(1H-indol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound Number 57) 2-(2,6-dioxopiperidin-3-yl)-4-((9-(4-(4-((7-(4-hydroxyphenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)piperidin-1-yl)nonyl)oxy)isoindoline-1,3-dione; (Compound Number 58) methyl-7-(4-(2-((1-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenoxy)heptanoate; (Compound No. 59) N-(3-(2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 60) N-(3-(2-((4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 61) N-(3-(2-((4-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 62) N-(3-(2-((4-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 63) N-(3-(2-((4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 64) N-(3-(2-((4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 65) N-(3-(2-((4-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 66) N-(3-(2-((4-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 67) N-(3-(2-((4-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 68) N-(3-(2-((4-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 69) N-(3-(2-((4-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 70) N-(3-(2-((4-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 71) N-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 72) N-(3-(2-((6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)propyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 73) N-(3-(2-((6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)heptyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 74) N-(3-(2-((6-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)undecyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 75) N-(3-(2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 76) N-(3-(2-((6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)butyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 77) N-(3-(2-((6-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 78) N-(3-(2-((6-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 79) N-(3-(2-((6-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-4-yl)oxy)nonyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 80) N-(3-(2-((6-(4-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)ethoxy)ethyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 81) N-(3-(2-((6-(4-(6-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 82) N-(3-(2-((6-(4-(8-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound Number 83) (2S,4R)-1-((S)-3,3-dimethyl-2-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetamino)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide; (Compound Number 84) (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide; (Compound Number 85) (2S,4R)-1-((S)-3,3-dimethyl-2-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamido)butanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide; (Compound Number 86) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(4-(trifluoromethoxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione; (Compound Number 87) 4-((5-(4-(5-((7-(3,5-difluorophenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound Number 88) 4-((5-(4-(5-((7-(2-aminopyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound Number 89) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(quinolin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione; (Compound Number 90) tert-butyl 4-(3-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)benzyl)piperazine-1-carboxylate; (Compound Number 91) (E)-2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-styrylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione; (Compound Number 92) tert-butyl 4-(4-(2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate; (Compound Number 93) 4-((5-(4-(5-((7-(4-(dimethylamino)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound Number 94) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(pyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione; (Compound Number 95) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(thiazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione; (Compound Number 96) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione; (Compound Number 97) 4-((5-(4-(5-((7-((3,5-difluorophenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyridin-2-yl)piperazin-1-yl)pentyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound Number 98) 2-(2,6-dioxopiperidin-3-yl)-4-((5-(4-(5-((7-((3-methoxyphenyl)ethynyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)aminopyridin-2-yl)piperazin-1-yl)pentyl)oxy)isoindoline-1,3-dione; (Compound No. 99) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 100) N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide; (Compound No. 101) N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)-3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanamide; (Compound No. 102) N-(3-(2-((4-(4-(2-(2-(3-(4-(4-(3-(2,4-dihydroxy-5-isophenylpropyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 103) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 104) N-(3-(2-((4-(4-(2-(2-(3-(4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 105) N-(3-(2-((4-(4-(2-(2-(3-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)-3-oxopropoxy)ethoxy)ethyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 106) 2-amino-4-(2,4-dichloro-5-(2-(4-(3-(2-(2-(4-(4-((7-(3-(methanesulfonamido)phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide; (Compound No. 107) N-(3-(2-((4-(4-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)benzoic acid)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 108) N-(3-(2-((4-(4-(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide; (Compound No. 109) 4-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound No. 110) 4-(3-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)propoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound No. 111) 4-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione; (Compound No. 112) 4-((6-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)hexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound No. 113) 4-((8-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)octyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound No. 114) 4-((8-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)octyl)oxy)-2-(2-oxopiperidin-3-yl)isoindoline-1,3-dione; (Compound No. 115) 4-((11-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)undecyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; (Compound No. 116) 4-((9-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dioneundecaffeine; (Compound No. 117) 5-(4-((1-(3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione; (Compound No. 118) 3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)propanamide; (Compound No. 119) 3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazole-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-N-(2-((3-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)propyl)amino)-2-oxoethyl)propanamide; (Compound No. 120) 3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)propan-1-one; (Compound No. 121) 3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one; (Compound No. 122) 3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)propan-1-one; (Compound No. 123) 3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)-1-(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)propan-1-one; (Compound No. 124) 4-(5-(2-(4-(3-(2-(2-((2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)ethoxy)ethoxy)propanoyl)piperazin-1-yl)ethoxy)-2,4-dichlorophenyl)-2-amino-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide; (Compound No. 125) (2 1 Z, 4 4 E) -4 1 H-11-oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffein-8-yl)(4-((4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)methyl)phenyl)methanone; and (Compound No. 126) (2 1 Z, 4 4 E) -4 1 H-11-Oxa-3,8-diaza-2(7,2)-pyrrolo[2,1-f][1,2,4]triazine-4(4,1)-pyrazola-1(1,4)-benzenecycloundecaffeine-8-yl)(1-((2-(2,4-dihydroxy-5-isopropylbenzoic acid)isoindolin-5-yl)methyl)piperidin-4-yl)methanone.
12. The 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound represented by Chemical Formula 1 according to claim 1, a pharma- ceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein the pharma-ceutically acceptable salt is a salt of an inorganic or organic acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.
13. A pharmaceutical composition for preventing, alleviating or treating cancer, comprising a compound according to any one of claims 1 to 12 as an active ingredient.
14. The pharmaceutical composition for preventing, alleviating or treating cancer according to claim 13, wherein the cancer is a disease caused by abnormal cell growth due to protein kinase activity.
15. The pharmaceutical composition for preventing, alleviating or treating cancer according to claim 13, wherein the compound has an inhibitory activity against a protein kinase of 80% or more at 1 μM.
16. The protein kinases are ABL1, ABL2, ALK, ARK5, Aurora A, Aurora B, Aurora C, AXL, BLK, BMX, BRK, c-Kit, c-MER, c-Src, CAMK2a, CAMK2d, CDK16, CDK17, CDK18, CDK2 / cyclin A, CDK2 / cyclin O, CDK4 / cyclin D1, CDK4 / cyclin D2, CDK4 / cyclin D3, CDK6 / cyclin D1, CDK6 / cyclin D3, CDK7 / cyclin H, CDK9 / cyclin K, CDK9 / cyclin T1, CDK9 / cyclin T2, CK2a, CK2a2, CLK1, CLK2, CLK4, DAPK1, DAPK2, DDR1, DDR2, DRAK1, DYRK1 / DYRK1A, DYRK1B, DYRK3, EPHA1, EPHA2, EPHA4, EPHA5, EPHA6, EPHA7, EphB1, EphB2, ERBB4 / HER4, ERK7 / MAPK15, ERN2 / IRE2, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GLK / MAP4K3, GSK3a, HIPK2, HIPK3, HIPK4, HPK1 / MAP4K1, IGF1R, IKK e / IKBBE, IR, IRAK1, IRR / INSRR, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LCK, LIMK1, LIMK2, LRRK2, LYN, LYNB, MAK, MARK1, MARK2 / PAR-1Ba, MARK3, MARK4, MAST3, MEKK2, MELK, MLCK2 / MYLK2, ML K1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MUSK, MYLK4, NEK1, NEK2, NEK5, NEK9, p7 0S6K / RPS6KB1, PAK4, PAK5, PAK6, PDGFRa, PDGFRb, PHKg1, PHKg2, PKAcb, PKCa, PKCb 2, PKCg, PKCmu / PRKD1, PKCnu / PRKD3, PKD2 / PRKD2, PKN1 / PRK1, PLK4 / SAK, PRKX, PYK2 , RET, ROS / ROS1, RSK2, RSK3, RSK4, SIK1, SIK2, SLK / STK2, SNARK / NUAK2, STK16, STK 22D / TSSK1, STK33, STK38 / NDR1, STK38L / NDR2, STK39 / STLK3, SYK, TBK1, TEC, TIE2 / The pharmaceutical composition for preventing, alleviating or treating cancer according to claim 15, which is any one or more of TEK, TLK2, TNK1, TRKA, TRKB, TRKC, TYK2, TYRO3 / SKY, ULK1, ULK2, ULK3, WEE1, YES / YES1, YSK4 / MAP3K19 and ZIPK / DAPK3.
17. The pharmaceutical composition for preventing, alleviating or treating cancer according to claim 15, wherein the protein kinase is any one or more of CDK, NEK, Wee1 and GCN2.
18. The pharmaceutical composition for preventing, alleviating or treating cancer according to claim 14, wherein the disease is selected from the group consisting of gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenoma, uterine cancer, cervical cancer, head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer such as leukemia, multiple myeloma, myelodysplastic syndrome, lymphoma such as Hodgkin's disease and non-Hodgkin's lymphoma, and fibroadenoma.
Citation Information
Patent Citations
CDK kinase inhibitor
CA3143813A1
Nitrogen-containing heterocyclic compound having kinase inhibiting activity, preparation method and application
CN105130992A
pyrrolotriazine as an alk inhibitor
JP2016520129A
Pyrrolotriazines as ALK and JAK2 inhibitors
US20120028919A1
Pyrrolotriazines as ALK and JAK2 inhibitors
WO2010071885A1
